var title_f31_9_31888="Coronal CT in pt with ABRS";
var content_f31_9_31888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronal CT demonstrated air-fluid level and gaseous bubbles within the maxillary sinuses in a patient with acute bacterial rhinosinusitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31888=[""].join("\n");
var outline_f31_9_31888=null;
var title_f31_9_31889="Macula densa";
var content_f31_9_31889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the juxtaglomerular apparatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The juxtaglomerular cells in the wall of the afferent arteriole secrete renin into the lumen of the afferent arteriole and the renal lymph. Stretch receptors in the afferent arteriole, the sympathetic nerves ending in the juxtaglomerular cells, and the composition of the tubular fluid reaching the macula densa all contribute to the regulation of renin secretion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Davis JO, Am J Med 1973; 55:333.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31889=[""].join("\n");
var outline_f31_9_31889=null;
var title_f31_9_31890="AF mechanisms";
var content_f31_9_31890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    AF mechanisms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 470px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Overview of mechanisms of AF. Four different positive-feedback loops are proposed as the main driving forces for the atrial remodeling process. Enhanced Ca",
"    <sup>",
"     2",
"    </sup>",
"    + loading during AF is believed to underlie most of the cellular proarrhythmic mechanisms (trigger loop). The main process in the electrical loop is an altered contribution of ion channels to the action potential configuration that protects atrial myocytes against excessive Ca",
"    <sup>",
"     2",
"    </sup>",
"    + loading. Abbreviation of the action potential facilitates re-entry and thereby promotes AF. In the structural loop, chronic atrial stretch activates numerous signaling cascades that produce alterations of the extracellular matrix and conduction disturbances, also facilitating re-entrant mechanisms. The main changes of the contractile properties of the heart are loss of atrial contractility which increases atrial compliance and the development of a ventricular tachycardiomyopathy, both of which increase stretch in the atrial wall. The circular positive-feedback enhancement of these pathophysiological changes explains the general tendency of AF to become more stable with time. It should be noted that the different loops are interconnected by mechanisms that are part of more than one loop. For example, increased Ca",
"    <sup>",
"     2",
"    </sup>",
"    + loading enhances trigger activity (trigger loop) and also results in a change in the ion channel population and activity (electrical loop). Re-entrant mechanisms are promoted by both shortening of refractoriness (electrical loop) as well as by conduction disturbances resulting from tissue fibrosis (structural loop). Like in a system of meshing gear wheels, one loop will drive the other, leading to progression of the arrhythmia. However, the proposed system of gear wheels does not start to move spontaneously. Structural heart diseases, arrhythmias, aging, or inherited diseases are required to initiate movement of one or more of these wheels. When the pathophysiological alterations eventually reach a certain threshold, AF will ensue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Ulrich Schotten, Sander Verheule, Paulus Kirchhof, and Andreas Goette. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiol Rev January 2011 91:265-325 [PRV1/2011]. Reproduced with permission. Copyright &copy; 2011 The American Physiological Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31890=[""].join("\n");
var outline_f31_9_31890=null;
var title_f31_9_31891="Grafting technique for Peyronies disease";
var content_f31_9_31891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Grafting technique for Peyronies disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 685px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Grafting procedures can be performed in men with Peyronie's disease who have a short penis, extensive plaque, or complex deformities. Grafting lengthens and straightens the concave side of the penis. Dissection of the neurovascular bundle and/or corpus spongiosum may be required depending upon the location of the plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31891=[""].join("\n");
var outline_f31_9_31891=null;
var title_f31_9_31892="Sapropterin: Pediatric drug information";
var content_f31_9_31892=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sapropterin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?28/21/29012?source=see_link\">",
"    see \"Sapropterin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/37/10836?source=see_link\">",
"    see \"Sapropterin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5568566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kuvan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13706445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/21/29012?source=see_link\">",
"      see \"Sapropterin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Phenylketonuria (PKU), adjunct treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants &ge;7 months and Children &lt;4 years:  Limited data available: Oral: Initial: 10-20 mg/kg/dose once daily; some clinicians report beginning with a lower dose and adjusting upward to effect while others began at high end of range and once response established decreased dosage to lowest effective dose; dosing based on a multicenter, case series (n=6).  Reported dosing tended to round to the nearest 100 mg increment so dosages up to 24 mg/kg/day were used; clinicians also reported positive response to therapy through dietary increases of phenylalanine consumption as opposed to significant decreases in serum Phe concentrations (Burton, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;4 years, Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 10 mg/kg/dose once daily; may increase to 20 mg/kg/dose once daily if serum Phe concentration has not decreased after 1 month. Serum Phe concentrations should be evaluated after the initial week of therapy or with any dosage adjustment and periodically to assess response to therapy. If positive response to therapy occurs, begin maintenance dosing and monitoring. If serum Phe concentration has not decreased from baseline after 1 month at 20 mg/kg/dose once daily, discontinue therapy (nonresponder).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: 5-20 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Oral: Initial: 10 mg/kg once daily; adjust after 1 month based on blood phenylalanine levels (if phenylalanine levels do not decrease from baseline, increase dose to 20 mg/kg once daily); discontinue if phenylalanine levels do not decrease after 1 month of treatment at 20 mg/kg/day (nonresponder). Maintenance range: 5-20 mg/kg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5568667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral, as dihydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kuvan&trade;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5568568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13706446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food, preferably at the same time each day.  Dissolve tablets in 120-240 mL (4-8 oz) water or apple juice; may crush or stir to aid in dissolution; dissolution may take several minutes and may not be complete (eg, small piece floating on surface of liquid); this is expected. Dose should be consumed within 15 minutes of dissolution; may rinse remaining tablet residue (with more water or apple juice) and drink. For use in infants and young children, sapropterin has shown similar stability when mixed with phenylalanine-free formula, applesauce, and pudding (Burton, 2011a).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13706426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture; may change to light yellow color over time, normal occurrence and safe to use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13706416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary restriction for the treatment of tetrahydrobiopterin (BH4) responsive phenylketonuria (PKU) to reduce blood phenylalanine (Phe) concentrations (FDA approved in ages &ge;4 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5568565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sapropterin may be confused with cyproterone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F5568582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Cough, nasal congestion, pharyngolaryngeal pain, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Abdominal pain, agitation, appetite decreased, arthralgia, bleeding (postprocedural), dizziness, fatigue, fever, flatulence, gastritis, gastrointestinal bleeding, GGT increased, hyper-reflexia, irritability, MI, over stimulation, peripheral edema, polyuria, rash, respiratory failure, seizure, seizure exacerbation, thrombocytopenia, tremor, upper respiratory tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13706417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sapropterin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13706418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sapropterin should be used in conjunction with a phenylalanine-restricted diet as prescribed by clinician experienced in management of PKU patients. Use with caution in patients with hepatic or renal impairment; monitor carefully; use has not been studied in these patients; hepatic damage has been associated with impaired phenylalanine metabolism. Use with caution in patients taking concurrent medications that affect nitric oxide-mediated vasorelaxation, including phosphodiesterase 5 (PDE-5) inhibitors (eg, sildenafil, tadalafil, vardenafil); additive effects may potentially lead to decreased blood pressure; combination has not been evaluated in humans. Use with caution with concomitant folic acid antagonists (eg, methotrexate) and derivatives therapy; folic acid antagonists may decrease tetrahydrobiopterin (BH4) levels via dihydropteridine reductase enzyme inhibition. Use with caution in patients with neurological disorders or receiving levodopa; seizure, overstimulation, and irritability were reported in postmarketing safety data.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13706400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenylalanine (Phe) serum concentrations should be monitored and maintained within the patient's target range during sapropterin treatment; elevated Phe serum concentrations may cause severe neurological damage (including mental retardation, microcephaly, delayed speech, seizures, and behavioral abnormalities) and low Phe serum concentrations are associated with catabolism and protein breakdown; dietary management of Phe intake is required to ensure nutritional balance and adequate phenylalanine control. Response rate to sapropterin during clinical trials was variable (~20% to 56%); assessment of response is established through therapeutic trial only and cannot be predetermined by lab testing; if Phe serum concentrations do not decrease after treatment at a dose of 20 mg/kg/day for 1 month, the patient should be considered a nonresponder and sapropterin discontinued.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe allergic reactions were not observed in clinical trials; however, patients with mild to moderate allergy (eg, rash) should be evaluated for risk vs benefit prior to continuing therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5568645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Sapropterin may enhance the adverse/toxic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Sapropterin may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: May decrease the serum concentration of Sapropterin. Specifically, pralatrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13706425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption is enhanced when administered with food; high-fat/high-calorie meals increase peak serum concentration and AUC by a mean of 84% and 87%, respectively.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5568572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5568573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Statistically significant teratogenic effects were not observed in animal studies; however, there are no adequate and well-controlled studies in pregnant women. High levels of maternal phenylalanine are associated with congenital heart disease, developmental delay, facial dysmorphism, learning difficulties, and microcephaly. Phenylalanine concentrations should be normalized prior to conception and dietary control with proper supplementation are recommended during pregnancy. Some clinicians recommend that dietary control be achieved for at least 4 weeks prior to conception; however, studies suggest that as long as control is achieved by 10 weeks of pregnancy, teratogenic effects of untreated maternal phenylketonuria can be decreased. The effects of sapropterin on pregnancy have not been determined. Pregnant women exposed to sapropterin are encouraged to enroll in the Kuvan&trade; pregnancy registry.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13706447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenylalanine serum concentrations (baseline, after 1 week of treatment, periodically for first month, regularly thereafter); children may require more frequent monitoring",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13706427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sapropterin is a synthetic form of the cofactor BH4 (tetrahydrobiopterin) for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates phenylalanine to form tyrosine. BH4 activates residual PAH enzyme, improving normal phenylalanine metabolism and decreasing phenylalanine levels in sapropterin responders.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13706428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 24 hours of initial dose, decreases in serum Phe concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 1-2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13706429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Enhanced with food; high-fat/high-calorie",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 6.7 hours (range: ~4-17 hours)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13706448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/37/10836?source=see_link\">",
"      see \"Sapropterin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Follow phenylalanine-restricted diet; take sapropterin at the same time each day with food; may cause headache, diarrhea, nausea, vomiting, nasal congestion, sore throat, or cough; consult prescriber if persistent or severe",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burton BK, Adams DJ, Grange DK, et al, \"Letters to the Editor: Reply: Tetrahydrobiopterin and Phenylketonuria,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2011a, 158:864-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burton BK, Adams DJ, Grange DK, et al, \"Tetrahydrobiopterin Therapy for Phenylketonuria in Infants and Young Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2011, 158(3):410-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/9/31892/abstract-text/20884009/pubmed\" id=\"20884009\" target=\"_blank\">",
"        20884009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burton BK, Grange DK, Milanowski A, et al, &ldquo;The Response of Patients With Phenylketonuria and Elevated Serum Phenylalanine to Treatment With Oral Sapropterin Dihydrochloride (6R-Tetrahydrobiopterin): A Phase II, Multicentre, Open-Label, Screening Study,&rdquo;",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 2007, 30(5):700-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/9/31892/abstract-text/17846916/pubmed\" id=\"17846916\" target=\"_blank\">",
"        17846916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koch R, Hanley W, Levy H, et al, &ldquo;The Maternal Phenylketonuria International Study: 1984-2002,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(6 Pt 2):1523-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/9/31892/abstract-text/14654658/pubmed\" id=\"14654658\" target=\"_blank\">",
"        14654658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy H, Burton B, Cederbaum S, et al, &ldquo;Recommendations for Evaluation of Responsiveness to Tetrahydrobiopterin (BH4) in Phenylketonuria and Its Use in Treatment,&rdquo;",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2007, 92(4):287-291.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/9/31892/abstract-text/18036498/pubmed\" id=\"18036498\" target=\"_blank\">",
"        18036498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HL, Milanowski A, Chakrapani A, et al, &ldquo;Efficacy of Sapropterin Dihydrochloride (Tetrahydrobiopterin, 6R-BH4) for Reduction of Phenylalanine Concentration in Patients With Phenylketonuria: A Phase III Randomised Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9586):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/9/31892/abstract-text/17693179/pubmed\" id=\"17693179\" target=\"_blank\">",
"        17693179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maillot F, Cook P, Lilburn M, et al, &ldquo;A Practical Approach to Maternal Phenylketonuria Management,&rdquo;",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 2007, 30(2):198-201.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17134 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31892=[""].join("\n");
var outline_f31_9_31892=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706445\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568667\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568568\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706446\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706426\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706416\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568565\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568582\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706417\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706418\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706400\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300027\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568645\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706425\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568572\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568573\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706447\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706427\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706428\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706429\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13706448\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/21/29012?source=related_link\">",
"      Sapropterin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/37/10836?source=related_link\">",
"      Sapropterin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_9_31893="PET CT panc head mass";
var content_f31_9_31893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PET-CT of adenocarcinoma of the pancreatic head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal (A) and axial (B) images of an integrated PET/CT in a patient with a large adenocarcinoma of the head of the pancreas (A arrow). The axial image demonstrates a lesion in the liver that is highly suspicious for metastatic involvement (B arrow). Both the primary tumor and the metastatic lesion demonstrate increased uptake of the tracer fluorodeoxyglucose (FDG).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Rocio Perez-Johnston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31893=[""].join("\n");
var outline_f31_9_31893=null;
var title_f31_9_31894="Malignant gastric ulcer UGI";
var content_f31_9_31894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1173px;\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Malignant and benign gastric ulcer as seen on upper gastrointestinal (UGI) series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper GI series showing the differences between a malignant and benign gastric ulcer.",
"    <br/>",
"    (A) Malignant gastric ulcer of the distal lesser curvature. There is the biconvex meniscus sign with a nodular ulcer mound (arrow).",
"    <br/>",
"    (B) Benign gastric ulcer of the lesser curvature. The ulcer crater has smooth margins and projects beyond the gastric wall (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy, III, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAR4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwLoaWkA5pe9BQveiiigLhRRRQIKXFABzU4t38kOFOCcUDIMU4DNOETEgBT+VaVjpryNuZQB70BcpxxjaCcA46etPdVJUBQfwrbi0oFcZBPTpUX2BFJMjE88ADFAirbWCTAYh259yf606/0w2zKyu2CBj61t2H7qIBYhyeuM03V23xKeB3oFc5WYnneOagbrWhfR7HYY/SqRQnJA6UDIxSmlIpMUDE7UU4D6UtACYoxSgUoFADcUEU8ClVGeURopeRuAqjJP0AoAiIpCK6vSvAHirVJNttoN+q4z5k8LRL+bAZrstL+BPiK5Tdd3ljagnAA3SH8elArnkWKMV7sv7Ps20bvEgDdwLHI/8ARlZWpfAnXLe8jSz1G0ubRvvytG0bJz/cyc/nQFzx3FJXofin4UeIdDiaaNFv4FGT9nRt+M4+7ivP2UjIwQe4NAxhFJTsUh5oAKSlNFACUUtFADB1pwpo606gAooooEFFFLQBNbBfNAcZXvXQw6fvtTFnByfmHrXPouGzhvbg12+lxgworMTuGOR+FAM5j7MyO27txzWnaCVTGGUYJ596t3VsBOw4x9Ku29qNq8E4piJraI43BRmqlxatvYAc5zmtyCEMuFB6dahltiWAGRx1oEYtpbs1yAOTVnV7Jo4kYjKkYHHfFatjbIJNxwCOO1aV5aCbTWXGWQ5HT0oA84vYWOcr2q54W8OXXiC5u4LVNxjgaRunGCMd/erepwBS/QNXd/BoQabbX17MfMec+WVBGAooGec6x4RvrGFT5e6VSd6gjkeo5/SuXI7d6+lvEsOkX9sTFP5b8n5CCRz0I9K8G120Wy1ObzkilgLsAyOA2M9eO/1oaBMwRRinOF3tsztycZ64oFIoAOat6dY3Oo3sNpZQPPczNtjjTqxxmoFXmvqL4AeB7bTPDcGtahYgardkyI8qjfHERhQvcZHP40CbOQ8D/Ameb7PeeLLjy1zlrCEAk8cbpA35gDt1r23SfCGi6Vg6dpGn2zf3orZFbH1AzXRpEoUYFP2Dk0CKYt8dsY54oEB5zj2xVxlxjCk59McfnS7R6UAUDBlsio2gBFaLKPSmFFA5/pQBkXFosiFWUEEc15D8SvhRZ6vF9q0aOKz1FRn5ECpL7MBjn3r3CRRis67RSvIFMD4Sv7O4sLqS1vYWguYjh426g4qvXv8A8fPDEU+mJq1nB/pdu4EpUD5o8HOfpxXgJpFJjaTFKaSkAUUUGmAwdadSLS0CCiigUDFqSLG4bhxTBUiDPWgDotNtTPErPn5TjrXV2ETNFEvbtzjHNZ3hq2Etom8gg+hrqIYTkEYAHc8UyWZDWLF92D1z7CrYhAUZz9BV9l2kdz+lDKzc8LTERwqqADaeatLb4UNzg+hpot1Lj58+tXGWOGMKWPzCgBkVuvBUHH1rVtYFCEEg7ucAg1kDnG1jitKxUqOGxxQBzmt6YPOYYI5J69qy7O+bSlkhkLiI5YbMZU+tdNrE7JMd33RXEeIblELYIzzgbuppAQa54guIZsW04dWzu456+orl727e5kDln3nO7JzmkupDKxYkZPNVjkmkUkHU1ZsbOe8uYre2jaWaVlSNF6sxOAB+PFSWNlJcXEUKRtJNK4REXqzE4AHvmvqr4O/DeLwnafb70+Zq1zGu8HG2Addq8deeT7fmA2c38K/gythJZ6x4nZ/7QiYSxWkbjZGccbzjLMM9iAMd692jTgAUsa4AxUqggdc0CGgUuKcOmKXFADCPTikI5NSY5pMduBQBERxTCv61M3HemsPpQBXZB681RlRWBIYEZI4ORkda02Bx15qpcDPfnFAHIeIrGO7tZYZV3K64P5V8cavp02mXstrOOYnKZ+nb619q6zhYWz2r5M+KqLH431ArIGaUIzgfwnaBj8gDTBHHHrRTnGGI4z7U2kUJR9KWkoAavWnU1OtPoAQdqUCgCn7eKAECntWnYWolOSuRVFIyQD26VtaQgUkAAnrigTOt0hyqqo6AZ4rpLY+Yh3AhR+dZnhe2EhJYAHHbrXSRwCNslPlJqiSjOEGNobdjqRUKAs2TurVurdH+6SNoFMSCMKep/wAKAK0aBGyBnPr60+VfMC4Qgjg89auJDGcghuMHNaFvaRttxGTxxnpQBz6K2Pu/pWnbRkxknJzTnh2XW0wsq4Jzjj6VdhXci7hhQOn4UAYOrIdzH5lVVJPPtXl/ieYSTDHTnH5V6r4sO20cx5ORjPtXkWuqfMBbOTSY0YjZzVm0h3/vD0HQepqAIWkAFaUC+WI9wIXpSGe0fs76dZ3Gr39zcxI11bpF5G7OVyX3EfkBX0ZCowBivkX4e+KJfDGsx3kcZlhPySxbsblz/MV9PeEvFWleJrZn0y43SIqmWJgQ8ZPY56/UcUxHRDqPpTgM4oHTpxThSEHbpSY9qdRtx04pgNPJoxS0GgBhBHpSYODn1p9NbjrSGREZqtcjjvVpuneqN5JtXjNAHP604SMnNfJHxRaF/G2oGDPITzDnjdtHT8MV7d8cvE11pGh7dPm8m4mlWINk5AIJOPfjvXzRK7O7PIzO7HLMxJJPqTTBDGOVAxyM856j0/n+dNNKaSpKCkoooQCJTgKSPqam2UwGoOKlVARycU2FflB6irMYwMEAigAVflwCc9a09NQ+ZwT07CqiplOcD8K0NPjIkbj8MfSgR23hicx7uDkZ4ruQVuLZc8Nz0HvXA6KTC3zcEnHIrqrOUhyM5BXiqJLUqnzTknbgY469KRVBJ2/yqOZ8QnJGcenvRaTIq4agC5FEN3RiMAEgVrWK7GUDkDByRWcZWkjxjA46DmtWwwqFm5wMdKAKrbS7s/LEn8aiJxkAEDsKszqodioweMD2qruI5x2x0oAyvEEPnabJgZKfMRXkevxgP3yK9ouF8yKVCOGUjpXmXiPT3WdwYztH8QXjpQwRyVpbE73YECtAxnykBB9sVfhgwgVRgfSnvECOcY7UrDM+3Bi6kjJr0L4X+IJ9F8QWrRGAJcyxQSvKD8kZcbsHPH/1q8/kXAI9KksZ2ik56buRQB9yRnKjBqReleH/AA2+KUdvaRaf4idEtoY1jguI4ySABjD469ByB9a9c03XtK1CBZbPULWVCMgrIM/l1oEatBqGC4guAfJljlxwdjBv5VMcetAAKTHPWilPBxQA00xsc0srKqlnYADnJ4Arkdb8feG9GaYX2r24ZMAogLkHnuM0gOnkdVHJxXnvxY8Yt4T8P/b4YPtDGVY9hJHXPeuE8efG2GK3CaDCJhLGGjeQFSffHp/hXi2qeM9S1h1XVfIlgLKXVYsnA7DJP+elMZT8WeJL7xLqbXd/IwX/AJZwhiVQf4+9YZqe8EAmP2V2aM9Ny4I4qvSKEooopAFIKXvSUwHW65Yirnl8AjHaq1mMs/pgVoKo2Z56cUCIoE/drgdRVlYz1OMfSp7OLdEhwMlRxVtYkXPAP1oAqQxNjG0kVradFmbJA9enWoEdehwMjjFWbVxuYZxkUCNqNssAeSetdTpyMxR+oIODXI2cyKVG8nnHSu5sWX7HGOMjnjFUhDZ4HMcbKuc5FNtoGMmX7HBFaFnhyYyCTnIpJMLIzEY56DFAGlZquPug8D8604I2JORhTxisGO4LACJCo4yevFa0MTsMu+FxnOQcUAWDbqfvAkj2qnsWNdrLzipLiUPF5YcjnqB1FUGRQSwkPtxQBZkQMWwu0j071yOvWY8xsqSQPTOK6cFcncxxjjisjVwGGc9R6UAcbd2gXaVA9CKzpUYZBFb15GzbRtHGenesydRuyfxpAYs0XOKrJFtkYHj0rUnTBPHGeKzywEm70oGWbZznaDgnnirqyMqhhwazYflOc81ZifPO4Z6UAatneywyJJGxR1III4I+le6+GfElz4s0qVLScWuv2qtJFtPySYA4IJ6Gvn2N1JGOv1ra0PV5NL1GG6hcpJEwYEdaBH0IviTVodK86/tLeC6XIkBVgqt/30eK8y0b4r+I7vx5Ppmo/Y4bNA6qsMRXkMNpJZjn0/GvSPG7xzaf50MqxuzFMNjB6dfXHp714P4/itbexuNZ0twuphgjgbTtIYZI/L8qAKnxp8VeIdR1GOC5vJY7Ek4t4ztRyCMEgHmuW1vN74et7yJPKLJmRR3IYqR9OM1s63c23iLwtbT2wX7Uqt5inBZHyM/mAfzri7PVGtILi1mQyQSHG0n7vY4/z1FA0ZbMdoGBxTSc/WjHyn2pvakUJ2o7UUUgCikJo9aACjtSd6KYE9kMl/wrUhJEWSQOOtZ+nvtWX0IH9aubv3Tcgcd6BFy3ZljiwcjaOfwp6yFVOSarQPiFVyOACalUlvu9aBFqPnnBFXEIBx1NV7dG/iI5q7sCcgDP1pgXbJQGGegrqtPuwsMeGII6/nXGrOw/OtvTn8xEAZQevJoEdrYuZeUbbgMfrxTWuIhGwOXb17VUtJ/KtSCSTs7HHcVVLbnYBiAT36daYGgl4VddpwvGQK2Irzfb9wBgCuaRlDAFsgelatpIgUgk/hQBaaXH/wCuoGmYD6VMXiII5Ue9Z9zIidie/WgCd52x1qtNIGX5j271C9wpPc/jUcjCQH5gB35oAz9QYQRMVzg9x61zlxIVKndnPY1t604EMSg/eyT71iTRB1U5BHJ69KAKcsofOSST+tZUx3MwY9eBith4QARWc1vls+vORSGQRzAjbn5gOasJKOCM+n1qsYyrc/8A1qsRjco7H07g0AWonJ5OeferNoTLcqmSSxCgDvVPO04B/CtDSSFv4JOm2RSfzFAHt3jm8NroVlHI2J3aRz6EnGf6V5LrYyZLdXDRXSMVGRyykH/GvTPiTvn06xeJeDDIwY9FO1R/SvG9WaSPUtNcybgsoSQE8Jnjj60xGF4PcR69NZuxEcqsm3I5YH/DNS+I9KisobkbTuXDK341Bolvv8cpFuAC3Ehye4Ga63xBGLsXcLYx5ZHB9qQzzODltmAS3AzTFXMm08UkTFXRl6gg1I2ZJXkOBk54pFEJpDQeaTtQAp9s0etHeigAo60lLQBZscbZM/7P9asOD5bHH4ZqtYnG/j0/rVmbmB+eo9aBFm2wFUY6VbiKg8KSR0H4VQgbGOvQEVfgY5DY/I96ALkDTGQErEseOcMS2fyxV9mARsdetUoh8uSa0Ybd5FyVIB6YzTEVmDSPjaSfatazjkVo1CkYPPNW7PT1AQhgfU5q3CgWfGMc9fTmgRs2iZsUzy/RiTzVO5Pk/wCsIHH9at2b4cxgnDcVm66WXy0AO7HQDrzTAfBKGcDOc9OtalqTnAz1ziuf0pZWcBQcZ6nNbsJ8uVSz8dcigC7JnIUH71JcRAxKf4xnOOmKcWUyBgSMf4UjsQoORuAz6cYoAyJFKMeevegjcc+o6VburYSrvj+VumM1XCMhy4x9M0AZGtx4SE+mR+orMQ4j+b+db+qRb4QMEsvIGfzrm7ncpwfwpANldScY6+tRSoMdM+lUzKSx+vFToxKnPNAyDgNu5B9c8iq5k2429BRdOVA2g1VXcerEY7UAWHu93yg8+ma2tAOb+1jZC5aVRgd+RXLyYXBBP1rpfAVxHJ4r0rzRuUTqe/YGgD2XxvORp9haQkyMEb5txGfmAORXhvie+cXUdpGhDJMuAD1IavUPGF39l06yu0T5jcNk57ZB/wAa8v1uO2/4Se1kRt3mSiQpk4BLUMEUvDYRfFN3Lc5LQrK45/i3Bf8A2atu31CL7fJBK25pPlAOawdHlRPF96Zx8rvMCM4/jz/SrFzbTRay1wvKA5UelAHK2cTS3UMI+V2cIM9jnvV3VkNrdSw5B78VDqTsmqzyABG8zf8ALxg9c0B/tUybULyuOSSTk0hlMj5c+9JTpcb2C5wD3ptAxKKKKBBRRRQBNaHG7Pt/WrMhzAc5PFU4D96pnbERH0oGWFfaB64q3DKAi9Tzms4HGKt2aF2BONufzoEb2n/PhjnGeldDGQsXfNc7aPtCjj2rYik+Q8DimSa9pL8rDtj9asLvEo2jIzzWVBeLGSCOvp0q/HcAgDkg/pTA1bEySTxhEJcsAMZ65q7q9opdT950PPHfNJouIJFlPzd/pUt1cLLchVAwefpQBkRiQHhSpOCBjFTRg8EscioZ7wIxyBgHrUZvN2NinJ/CgDTEuGxnj2+lSo+8cEk49Ko26PIAQvrzVq1BQjLEn0oAmuEaOIZ4Oe/Gf85qpluep55qzcSyuAoRcAHFZ7GTOSx6dCKAEu+g3DNc5rSAKrKCOvAHSti7diG+U/hWPfNuTlTg98dKAOfc4fjPWrBfC9f/AK1VrjIlzjJBx0pQ+eCBkAfhSGV7gnbyT7ZqJSNwyR9adKQcjIzmoFdQwzg0gG3A+Y4JOe9bPgZgnirTCeQJxj64rAnYnpyPepdNmkhuopoh+8icOo6cg5oGer/EWYR+F7Nhk/6XIDj6LXEeL4YrXxBpawoiqsmDtByTuHJr0L4u6aY/CkVzAwFvHqCN0xhZFBH+FcN4ygWTWdLIUkmXnA68g0xI5DWY2i8T3aoxUtOSGB/vH/69dPao8tlJNMWKt8o47Dis/wCIFiLPxPA4GEmVH/HPNdjpVusujZCjaGPGOOtAM8u1qHydQZQxYEBsmrth5VlppvSN0/IQEdM8Va8ewLDq8OxQFNupOPXc1UNPt5JrEoI926QY/I0hmT9fxpSOO+atalb+RePEONoGc+4zVZ0KgFuM8igY3FAGTWlY6TNdWklyuFhjBZmPQAdTWa+3cdmSvYkYNACd+OlFFFAhY+M1Ix+Wok707oKBko5/Crlu+1AFxVJT2qRGx0oA3rWUDbnHPNafn4QAcjtXLpN3BOauR3DFfmb8KCTaNwM/QZ4q5aXqhkJPGefeuq+GXhO21S7uY9at5i4iLImQAOnJ/Ouyu/hPolvaz3LLfbB8yosy5Jz7r0pgcDpWpNcSbY0MhB4UDNb/ANluY1WWWF0DcglcZ5rqPB3hGxtYrmeK3mO7ICysD39gDipbvTryzfzYZmSEP8ycFQPcUxHl81tKXy/yr69c1YtXhXAwW+tbHjDV7YSDesLKR0MKZI9N3WsG2s4Ztstg7EbQWRyMg9ePUUAb0dxttmKKMgcDIqpHdvjldufWqBlYZBkA/EVVjALuAVO31IoA3mvOCNwyM96RLhSG34OOoIrFuY3RlZD9eRTPOkDYIOO5FFwNaZ4TglF9iKyL9QwPAAyRmnu524BwD0yao3cvygAg4BoAwdTbYzEEEf8A16pifIyAPWn6y4GB/EazUkGOT2qSiaSUmqrydulOY+/NV5D83HSgB5bI4NIrHJGaizSg896Bn0auzxB8I4Ipo1lE8DR5C5IlRQY+/quM15xNK91eaGkK75TLh8jturovhJqgk+HPiixuWCpaIbmNjgbD8vf8ay7K3WPx+00EYEboJETjC7vmHtx0pknOfEf/AEjxZaxAgE7E47ZIrs/DFqE0eWNSCQ2R6HmuA8SlpvHUcZGX+0oD+LA16FYyR6Rpkl1fN5cMal2Przxj68DHqaEDPMfGcp/4SCXfhtqgAdgOcVr+CLEiwkuJgG3viNT6Ac/n/SuPnln1K/aRhuuLiThRxyTwBXoUdrcWVnY6fCqI3lB5T1JfGCPpQhs891Cc3F7NKTuy5wfUU+ysZbt2JzHbxjdLKRwgxn8T6Cu5sfCum2FmL7WJcRxYLg7cfTB7k9q4nV9Ra/nYhRHb7iyRKoUDjHQd8UguWNd1gX6pbWcIt9Pi5SMDBY4HLc4PfFY9LSUDsFFFFAgTvTjTV706gYoPNOzxTKM0ASB61NBUS3rM5ASKJpWJ6DaP8cVkZp6O6I6qxAcbWweo64/z6UAeo+BPF+qpqyPDcQQWbSeXh9pJUYO3p+tfVdqEu7YDAKMAfpXwjolwbfUYX3hQrZGema+qvhf43XVrYpdLHChwYnMvL5OCCMcY/WmS9DvLuBbWM7AMHsPwrjfGuoCx8N3SEgzzAEAemf8AIqx8TfF8GheHLm4hnQzKQo2MCRlgCP1r5u1T4halq10ZLpsJkKq5HC5+lArCahJPfXDSyuI41weSBmpNMv5rZleNtpToQM1zGqahPLKYidsa/LtHfB4p+kzus53NmLGG568cc0Dsdot2t3LwVSc8nJADH29KlgixMFb7zBsjvwK5WK923I8vgg8NnPauzhzdW9veEjfjYeeuB/higQ4QNcwOqsFcLkZ/CsZ3lifbu5rat5fKDBTgkYqjcoJ2k2k7hzyaAK5nd/vHt69KgkYng9/SrMMYYY7/AFoe35AzkHPegDi9VlMl1IeODj8KoKxrSv7cpM/ORms5uvXpSKHAk8VG2ehpVODwaDlu9AEdb3h3wrq+vDfp9tmLn9452rxjP+elP0bTbaC0j1PVeYi37mAnHmY/iPt6D2r0TxN4vuNI0b7DYtG1zcg72VhhOBz05+lMGyGHT4/CmiXOhpewXeo6jk3MltIDHFGNpCg45JPf2rV8LRW8ut3E3/PK3wSTx8rYH86xPDVv5NncX9/MZpZEyd5Azx/9auw0S0ji8LXWpjhpRgDpxkGgk820OxXWvipcZ4WGR5ceu0gf1rb+NlwLC1ttNiOGuVWRx6qpOP1H6UvwUga48X61qBGYyDGG92fcf0FYXxlvhqvjqSOPPlWgFoO43Akn9T+lA+pH8ONDheFtZucF438uBCeN394jFddGu/U4mgcvcOMbsjoM9P1qS0hWysrWzhKJHbxCM7j96TuR9a5HTPEU4tNVvPkgktI/IgfPDMdw49+/40C3KvxE1XeE0qMhlSQTO4OecHA/XNcIamuJ5Z5Wlmcs7HLE1EeR0pFoZSmj60UAFFFFACDpS0i9KUUALRRRSAXFL2puKWmBJGdhVwRuB6Ht713ek+NV0zRYxBEwukXbGNx5YEfMTj3z+lcGEJBYA46E46UnpQK1y/qGr6hqLyteXk8okYuyGQlc5z0zVEUUDrQM1ZLJjLEGIaSRA/Xp9asrAbVAZkwSOAKboqTXl/GZJPlJAO4ngV0V1DbtCh8t32k4eRiox7Cgk5/TzvucyYIHv7V3djdBdKQE4QTfKP8AgIrmrC3U3AIjGByABxXQWsVzd7I7O3eVQM/u0J570wY6biYqTkD360iW8nmSNjCMp45rUGmTgkzmCJsZwzgn9K1oYLJLaRJAJGAOCWxnI9qYjk0R88UPCWweQTXSROC7RiIIg4A9KkUFW2mAXCn+6Mn8aLAebavasJXKqSG+YVzEqYcivXNW0+2vJ3W1kSGYf8snDKQfTkYrgNa0K8tZGdkQjPY8/rSY0c6F54q3pqW5vYBeE/ZjIokx1255pyWj7cnap64ZsVPp2mXN7exW0MLs8jYGAaQzqNUjmvvGwj+zuttbY29dmFXjHtWbeQPf61PHyULBQwHHQZru9Us3spLiSWRGcW8VuNuSTII1Vsn/AHgao+HdFea6BjKMcYJJPLH0pklHXpZLY6bYRLkztg4J6cV6v4ptP7N8DGAZUxxhcdyWIJrm7bwjdXnxMNreLELfTYgXk3NsYttOFOOTXs00Nnqlx/ZwsGmtww82VgdvHvj+VAHnHwn8M/2X4U/tGVCj3BklYHPQEgf+g15dp1ql943upXXeqXPm5992RmvruOxt4rMWqQotuE2CPHGPSuXk+Hvh+Nrmazsfs1zMQzSRyP1Bz0JxQB5ja2EEm6+uIQLWwT7RIvOWYdB+JrwTxDrkmpJFbxwJa2sJysKNkZ9T619IeMNNvvDfgDXndQzOEYNGCcIrA88fWvlaQ7mJIGSc8UMaIyaCeKDSUigIpKU0nSgA70nNLRQAg6GnU1adSAKWk/CrmmWMt/dLBBsVjzuc4AHqaYFSul8LeD9U8RTzR2tvLEkcTSmaSJtmBjjOOuD+Nep+HfA0MSxaTcW0EitGkkVw8YPmTFcncD/Dk49sV6v4O8M3emQSi8igDvwdgByMf54p2JufL2vaBdWNhmzt5ntLdf38hQ8k4+Y1ymME+or7M1rwdG1nNb20MaW85LzcDPSvA/HXhS00rRdSXy4UntHV7eQEb5QXwVJ9NpJx7UAmeXU5RntzRtPJqSNCThTk+o6CkUd54T0oJGJpHRnZQcICQvfk5/lViTSpppY0HzNkK0kz7VXNHw60q/1yWSzs4cWsSI0zBgjMuepJNesf8K8M2rfaJwkWmtZpEoXadkoPUDv9e9Mg4vUvCX9hXFpFNPHeSzp5ixICEUbc/Mc5PrVOee+giM0k5jt/uJEpKoxx2ArptY027NnchnB+xyLCHdAXk+XoMHpXPapbwRxAWwln1edT+7lTgAjBxzgkY4+lMCixZrl0nu4VYDlEYsV6enFaraeuCzSSbe7dB+XXvXMpozrbmWE3QullwxwuGY46c9sGvStKifTtWnbUUF7DdJtitygYgjGWyT+H4UAclqFvd6dc4kO5WG5WXP3fU1YttR+zgFgd3XODmul1ya1W9nZIlB3Yw4zsx/D+FY0kUZkVirIhJ2snQ/rxQBB/alldyf6XCSwxywNa7QaDLpyvGWkY7dy7GIDH69ayysVu0rSvlQNwwBn0rTsdXtJx9kidPNjUfe4yfY59qAMS6iSOaOOPw7FcROMiSXeFP4girkd9DplrkJp+mheskSO7Lx0BZjzTNJTW9cnks306W0g4YXDMMJjOT15zXPa7pMIvImjna980hfKxgBsdznvjNAHW/C23fxPqKaneKq6dBI6RxknMhAHOO/3uvSvXV8I6bB5lzZwiMkEjZnhsdetcx8PvCrwWGnTzIkDrlkWMAKoK4IIB4716lY2ggQoPmX3pAYWgaNENOAlle5mZi8sr8Mzdv0rpbeBIQBGuAKSKNY0YIgUHsO1ToMKBQAhHFIFxz3p2PpQaAKV/Zw3lrLb3MSywSqVdGHDA18efFn4cXfhTXJDpVlez6M0YlEyxs6wnJyhbnpgHJ9a+zJgxibZjdivK/jVoeu+IfDzWemKsasFZ/nC/MCcgnPTFIaPj4+3SkrR1vTjpWovZtPDOyAZaLoD6VnEUFCUGg0fhSASgUtHamAi9KWkXpS0AKOmTXtvgX4ewf2bpN7IS0l5EJXc8FM/MABn6CvExXuHwo1LVJrSB9QvZ2tFfYkSKo4xxTQmfQek2FmlvbEW6b41AVioJHFbIU9aoWaxm2jaNSMgHHer6sCOeopCI7lS0EgQDdtOARxnFfMPxr8PvpkEl7dPJNcXkvlxxomVQ7gxbOfQEfjX1H1Jz0rzz4s+G7nW9LhSyuBBsYtIAqksPQE9KYHx4YZPPWEqVlLBcNxgnpXWeEvDv9s3UUPmAQCRVYonzOCTnJz/jgViXOl3UetS2McbvOjsibsZb5toP6/hXe+Atbm0R7vTfsix6orGLc4HqRgA96Q2epeIPCx0jSxdaTHHA626RGGOPAlAGCWOfStbR549X0C20+OY213bxIzKOQ3Xg8966vwjcS3vh+0OqqDO6BSJAATxXBa7o8/hfU9RudL0ie/tb8ZmaAgy5yeB7UyTTitW0EvcRBprWRQsg27ij44IH9fauA1cWBvH+yyXsd0+5N08YzyvJB3ZFa/h2S6vtLENybm2tIpFa3uPMVeAvKNz2rk/FFjY2Wp3sVrc+bJGRIgkk4HAJwQaYGzpcNrL5Hm3Rl81HUhflBbGBk9//AK9ZNxaXqSyppplQBGiV5yAsecbsc9cd64uTUpntxbCXaiuzAk9jjj9Kkvb1Zdq3U5kbGFYt93gUrgdRbzST3KwSS7liG0ZUfMc/ePNSXEJsJT5k6RMf4QevNebyy3cBkbfhF5G3B7006vOYh+9dmHQNjAouOx6dbW9vcwM8khmPUAnkc9jT1s0jWSaG1UbCB5mBwa4bQrwvBOZpwrBc8MASPauz8KahDHpMttIZHjbDqCBt5zyTTES/2zfajFDHD/qYCCUI5x0z9K6Cy8FTJ9lvNMjLGXY0pzyuByMk+9cFp5uItdmXSBsVlPm5+6WIOME+g5r3bwYJdM8PWmnO++5VQ3zsO/PJoA1vC1h/ZWkW2nwsz3MbiVpCoAJZc4611encSyruJJw2CeF4GcUWduqQo2AGI7dKtxxqjMyjBbrUgPc4U8E0oORmo5Cei8moYpX/AHisOQTg5HI9aYFvOO1Jn14qs8yoEQthmOOlVZNSjiuCjf6vgK2fvMewoA0icVheJbC51O0NvBci1QkFpNoYsMHjrxUr6zauoCzxFw+xgGBw3p9ao63eC4t4jby7ZUJcAdGxkYP+e1AzyvU/h/o2k2bHVLe3uLcy/KRAokdiPb6V4J450W10bWpYtNm82yPKhj80Z7qe5+tfSvxMtNTudFtbvRLvy9QWSN2hKowKgHcAD7183eNrO6j1B7m+eGS5uCZD5QwcY6kDgcCgEcwaVR1opR0pFDKKU9aSkAgp4KbPukvnOS3GPTGM/rTQTtK5O0kEj6Z/xNLTAUcV7n8HLpbax0+znlRXlcyEseikfKK8i8L29nc6zAupzRQ2YOXLvtzxwPzr6M0fw3pF9a2l3ZBhhR5bI4KsMfSmiWeu2zKI1AYY9QfarauCSOK57Q45BbRpKDlfl5PXFdFEgUHk/nSAeBXP+MmMelSMkixyAHaxPHUV0DEAnJ/WuM8eSSSWvlqhePd8xB5Ugjt3oQHgni+2j0u6tb+4PmsrufkIB5xyOOuR+lXbUafcXOn6na35nQL5iuGAYODyG9O34Ve1hrPUo1kiljW5gfZ5ZIyhLDDfQYqGXwmsdrff2c6xmTbJNMGDAkkklBj6iqEemX+uxXnh3S9Ttg/2yErIFRvl3cZDVgaj4g1nUb6BxvtbeUYCk/KcAk849q57RZGgNtcR3MkQt2XMbn/WYxx07+lbXjvxpa3vhK0j0kiS7kbmIHBTA5/WgDltavbvSrC50e3uBCyyb0LpnC4+n+c1h6hFDc6TbXck8Ut+AEIVgRwPvEelc/rPi671HEFwx8tMEgsM7gMelULfWFQbVOO31OKVx2Ibuyudzyhw2SScfX0qhNFcZGQcmultbuLaN7oFHOeParDzxupClSvqMZBoA5620+5ngcFwDtyoz3yOv61Yj0KVRy6Fs88cCrv2tIS2WwuQCM9KJtQlltsWo2gn7x7+tAEa2tvY3EO9l80DeST9eK0Jtdjkiit1zEoGMIc7uw4rGvraaW5Dzy4DKMkcYp1jaq8qFeQuBnPWgDt/DOtw291bK7P5aKzKuARwDx078V6to3jGa8toJJ7BIFYhWkLbiBjjsOvWvH7GFFjDKuNvGT3qRb+WLUQJJznggZ644oEfSGj+IkvLqW3WVP3AGR2bI4APrXQSalBbW7TXskVvGoyXkcAfrXgfhzx1FpHn3AhaVeu0kdvQ4rpbO41bx8j3BiS20y5OxYi2SuNuWzt5FAHVp4/0q81F47KTzVRW2kNgSEY46Vyfxe+I9zoVnY/2NLEk827eQQ44xgdKk1DwzF4ekEixtPYc7mVdpTj19+lVtT8GWPim9tJIZkWOIkrGHyCMjg8cDigDibb4n+L7rQ5JHughGSNsCjK57Hbk/nXNR/E/XINFNhLeNJHJJv4OHTnoGxmvZ4NBuNJvFspXzaMwSIIehJwR0rJ1P4brb3Cy7kuRMShgmwS0ec7c465PWgDJ+Hnika/qYga0aO5MiOZHlBHmYHOMdTt/WvTTDeS6o91bxhYYIFiMWeGYsxZhx7gf/qrye10iP4c6w91M2+LCzpufB3gkKhOOOePxr1iHxAmq+GIbvw9c25vJ0WQwPKFZDjkHPoeKAPOvHNw8umia51FUErnbLGcEx44IH4GvAtW1ee5MtvFcO1oTySMGT3bv+FfROl6bc2PhmYa1qSLM0g2Tyog3hk5RRjjv0weDXz1q2mC109rlpEL/AGx4sKeq7cg/p+tDGjEo980uQehBpppFAeTSH3oooABS0gpaANbw3pseraolrLOsAKkgk43H0r638D6bHpegWEAYNHDEqrjoeOo9q+Q/DwVtas1d9gaTG7GccV9LWHiQWljFYj7yKiIMnJGO9NEs9Mh1FCQqpj/a/CrqzuSGDAg1hPbMumxzA7T5eWyO2MmuX1HxLdWemyzpEwC52Bs8t2z7UCPTPnOWY4A9K8R+L3iG5XWbePTNQj+0RNt+z+aVxn+9irlt48upbW6hu9Yjt7hEMm1YWOAB0zXh/ifxlNq2uz3ckNvgzHbKseH2bu3PUj1oHua3iJJvszTxxzrq982wbJDtBBBZl9u2ffNbvgvxjdNpAs57cmRY/LLNn5+vFUJprq3gGqWOnyalaOkYiZoXLQg/e245B61iPe65I622naelqiIQDEjfOWJI+Ynqc9KAL2svPfxubKdkmjAZowxGwk9iK4M3l0rEi4nXd1AcjpXU6tb3dmGjmP2OSfYXGSMY/wDr1izLZFlFxOrEKMlAck/UcUAjHCk+tW7WxeZgAcD+96VpC10pwphvgHPVJEZT+eMVoW9jJGqrBCkwPeNif60h3MW4jjtwVWXew4IzRb3GWfOckdcnk1tv4deSYmS3nQdSAD+fSpZNAhjfMazqRyc80CuZj3PmxlCv7xcN7+n4daagu5HBXdtX17HNbtvosalysnzYwWYEd6uR6NcuoEEfmZz93OOtMDEeFp7U+YkjFTznr/n/AApIC0Bj2AhSB8o711KeH5Ex9umWAE5Ksdv/AOutTT/C9nMqzWlxHckKAY1JyOfzNAHOWt3PJG3VcdNp6UtvGbqYsQcqcHA5zWhrtk1jaO9tCd/+yCa57wjBq11rsNskUpjlkIZmU4U4J/p0oEeleFtCF00SNCCpOCDnPv0r3mzktLKzghjiEMeNkaDsB6fnWLpGi2mkWFt5SAXRjVWZs+nJx2yc07UtQtLOZZNQl2W6cJwWJY9wByaANnWZ4oYF8xWxLlD3znsfauF13xJZ2Nvc26TLZrGnysgO4NnqMetU/iN4tSzs8R3GEceYjEEYXAzkda8H1vXZNc1KGDSWmaESCSWWQthjn7vrt9vegD6L8MeN9PuLW3guZHuZ2UgSMDmQg8Z967Sza31WGC5EX3Gyo9OtfP8A8MvDNxPdSvcTzIUUvHHECwznouTxXs+i3Mtk/wBisbaSdwR57tnbH7E0AQeP/Cdtr8EatAjMMAlmI2jOQcex5/CuV+H+hR6RqAjuUmM06HaJh8oK53YPocg16zGvmhZGXbxgqe1cv4i+3Lcw2mj2ERKsrmWbITac7gCDkHgfnQBpT6PbX8MQniQtDIHXPQMO/wCprhPiJ4Ls59N2WUKWhzlp41PyDHLE/gK9Rty32ePzAofaNwUkjOOaranYQahb+RdIXjyGwCRkj6UDPjj4i6U8dxEtojzw26yFplViAuFI3HseGrgWGCc19peMfCmmjT9SbTtNX7ffW/kFkBOBgAHHTjFfN/xe8NroOo2ccETybYcS3CoQrEBevYYyaATPOqKU0nakUA6UUgpaAJI3MciujYdSGB9CK9r8CeKrPV77T0ufLSRFxOGU53YP5jNeI1e0i/bTr+G6UZ2Nkgdx3oQmrn2tPqFvPDb2Ucy+dKBhOc7cVzHxP0Oa9XT0t/MW0Rm88oeg+XBP61zHgrXv7V8U2ksEQGIFAJ6Y2fXrXr1yn2uycIAzEco3f2pkng8vhG7udP1Gc2ztc7TAFwRiIj5nx3rzo6RPpGvskQSGGMj9665dh3IBPHI7V9CarpOo6h420XUNIRYLe2ikju4ycZBxg9ee9c74m+HN/qfieHUTNEoRw2wDO9cglev60AUp/FQ8MeErBZ5IrlZ0cmby2DA56FR9QOfeuI0jX4WWXVzFKCjASgMQucnbkD+Vex+IPAKav4aWxjuFtyCXdUTJzySAc9zivBZ7C5sZrnT7ZSkUMhE0UYBLOMgbmPJ/KgDC8UXk+p6zJcXLFnfHXOAPQViH71bWo2V1HM0k5CljuPJOKxsZPAzSKEDEdDWvo0bxyrMVYEcjBwKXT9HkdUmlU7W5ArYgtT8oUYHpgUA2WG1K884GGSQfLnhjVk+JNQjUKyxSDkHzFzx9af8AYmVenO3HT3qhd2LGB+oIHNMRZGuktzaW249xu65+tXrPxVdwuqxNHHj+6v8AjXLCOUAbhn3FAk8uZSo6deKANzUdWa6uWmmw8xOdzEnvWFPqE6yCRHaNl6bCRg+1PnZZGBUemRjpVG6wOD+dAGxZeMNRiTy7zbexYx+9yG/Bh/XNer/DG5tbvVbaxm0+e2vQY7yBy+4SI8YPHGDgV4t4ctlvPEGn28gBR5RuBGQRjPTv0r62+FmjyQeFdOl1SygivowyxEKN6xEnaCevQ0AzavNRhVJvtUbRQJ0eRSFcgdj3rz3W/E+j+VPdNfRKdrYkeCVvLAA+6MV61cWNvcxeXcwxzRZ3bHXIz9K8z8aeDoZLjyNPgSK0nBWVAnCjjp9aEI8S8TavoOqZjGr3LAZzJ9nkw3tg1m6Xq2g6ZA/lSylx02wsS35nAro/iD4STS3eKaFo5ViPlIiKEjXj5ie5J/ICvKryE211LCxBKNjPrQNHofhjXb3VNQlt7G6fS0l+SOVHfzJSWHy5BwOB2+le2fDK31i2vGglEs1vC22WV9wycnoe9fLmjqJPOLGYCBRKGiGWjO4Ddj6kD8a+s/grq11qHhOJLl3maNiBLIuCwJP8v8KAPSVIIH04rL1WVLdopHICgksx7DBOf0rVUcDNZmu6Wmr6Vc2UjeWJ42jZgMkAjHFIDnfh/wCNR4tjmkSxuLeFSfLkeNlDL+PeuwGCM9c15XZwa94c1e10SHVrGO0AUQyzQks6qvTAOAccde2a9PWVREGLAg9+1MBtyqhXY44Wvmf4hyX3inXvEtnCEgTTowUbb98MgyrfXNfS7OJR6Y6ivA/jft0JdWuraJDPqZVMouGyIwpJPoBQB86SoUdlYYZSQR6EGo8U40nekUNHSlpBS0gFpRTe9LTA2/D3iK/0K7hns5D+7yQpxzX0hoPxBsLnwxFcmYrczZwDjIbAyP1r5WFKODkcH1FArH3F4Pnie3eGZt10MsxI5x/k1tXNhHOM5ZWHQqcYNfGtr471tZYWjvzauuN8igfMAfp+lezz/FpNNvreea4S406dAcxlW2557dxTEdj4s8Qz+FGgkvIZLuweQI7xAb0BIAyOM9f0ryj4hG0iv7jUdKmkW3ul855QgAT2Pf8A/XUXi74xWmsb0trOURAgYliRt4zzwentXl2v64dYvIyYzDax8RxKenJJJ9+aAsO1q7V7ZI9zMxO/J/WqFrZyELK6kIeQa1rK1F6kYZAYwABn0z610CacLtorW2Vd2AACQo49STigDG027myY9xKjp+Vdn4Z0PUNVv4rWKBVdhuJkUAAYzW58JPD9jPqs93fwCaG34QOgIL47g9cZr2rTtNtLdhPHGoMp83dgZ5FAjyy+8N29nrttp7B2ViolkAHQjt/k1J4r0G0t53ggshHEPlLHGSMcmvT9TtrZ5Vdo1WbO4NgZ7Vz3iu7t4ZokkCGV853DOBxTA8c1DSIbXzJI428tTgEqDnmsm8gsEWNjbkueWwAMV6H4pNq1mDtZGVucYG45HNc9f2NtPp8E0flqcYySMtzQByD2lrOf3Ucy/lxWTrOmvZIu5t27BxjHHNdjpNorXYMjsFQ7ivHOOn4VZ121t75RtiEjoMYwAf8APNKwHnuipJBqEF0jPHJEwdCvXI7/AEr7J0PxNYy+HbPUJZkVZlUMPRyOR+ea+ULREbUYDBDvg8wBgMZIGSefw6V7R4ZlSycBpLVbCOPcFZUO0kcBs/h+NFhnrKa9YGeKCSdY7iQbliY4YjGc4qfUbq1gtWnuGURoN25ug968c18rqt7Hcm4s0KxCSTBVSMKQACOSCeMA96861m81jRbmaNJVVXXMkQkXJzgjrwcjFFhG58ZdYvZb+7lsYpBA42DzCMY2gM20/SvDpWZpCXOT3Ndx4h8Va5PNLZS3UVwVzb7ZLWIsoI4KttyOPftXFT20tuI/NQqHB2nIOccUmUiXTbt7K6SeL/ddSMhlPUEf56V9g/BjV9L1HwhZrpaFEjypVwNwbc2c/jmvjVa+g/2efFmk2ulHRpyIb8PuBfaPMJYkYPfqBQDPosds0Gs7T9RW7Ljyni2kKN+Pn+lX88DAFAjD8S+GbDxDCkd9G+5G3LJGcMDj1rB8K6BJoF1fWNzdTXNo8oeBpTlgu0YBI9MV3B5FZt5avcXA+ZkUHO4UAXH+VeFHT0rwj4wRy3+najcXSM0lv5sEMKAY+ZB8/wBfr6GvaJmQW7wPMQcY3ZGRnpXlvxFsdORYbWeKOKJpDOG3AZlA+U/zpoR8qmkq1qSBNQulByFlcAjuNxqrSLGjpS0gpaQBS9qSlFMBR2p1NFOoAcKBxnHSgUtADo03uqlgoPc1etdMkuLjy43Vh6iqcUbSSKqjJJr2X4S+CZNWdbh8i2jI3HHLdeF4x25oE2c3p1k1jpu3qxAxmu68E+FW17RL145BHKkiEkclhzkY+p/SvS/Bfgy1tbR2v4vPuDITukQDgdAAansbP+xfEjxxQrDb3IypQnaWGeCMUyR/h7SLfRbC3toycknLyHksRya6WRQLRQMfKvFZOvmLZDPLOqQBvmOQMHHXNSRX8FxCyLMCcblKt1GM5B/woAS4RpmyDnC8VwHixPtV0yysUZASp6YOABVvxT4ke3cm0uZ4GI3MISm4YYdmVhg59PyrnPEetx3lp9tiMyhyylcj5GAHtz6/jTApPcC7s9soBZTjY2ATg1j3ChY5YpptoUn5eDnniqsl3iJizN5wbruBDVmTzSXM+5pW27u2OPfpQBVfVfst48ZVGjhZQzh8Ec9qnuvEv2iFktT5SyAfMMMd3+1XHyzf6beI7MVkkJ6A4O447VBas0TqyyHqCR60rjsddots73yiRoztPAJ7kYH612cGooLGW2NurwF13Mh2knHPP4V5zBrcnnxhPk2nKc9DzjmvYPBHirTL3TU02/skBhXLOCqiU/XHH/1qBF6zhtokhtZrN1t2WNRN1VsgELnr1P51BqfhOGa8lvZZSYsBDEBnAAABHHXivQ3eC4MTTtFHZyhdkbcEHAI5qa6W3JuLzz9iRjYiSOoRgAORxTA8V8S+Frmwmnk8rz4tjSSuvIPtnsf8K4V9NtLu4nW4nEVnG/zIuAV9ME/zr6H1y7trbQ5pkmSS2cux8phgqV5Gcdf614Tq99bXEcVlb2zJBI7Py2WYf7Rx0+lICbRfh1pesX9jFZawGWTLzRMfm2+isBgmsnxv4Jv/AAj4lhgtJHMM6mS0uN2CMZ+UtgfNx+tejfCbw6ia1bXPnu1tNH5Maj/noGDMw46KvH4ivfL2xiuLRrZ4klQjHzqD+PSgZ4D8L/iVfILaHVm+1MFWLzp32sOele96Lq1tqtus1rPHJwMqrAkfXFfLPjLwZrFteyTLbSadGJ9satnYSScENXq3wP0TVdPWefWSUdcBOg3gg5PAGR6UAexBvXrUU8mxCetJI6xplmAX1PSq91+8QqpG6kB5F4t1bU7qXWryyYWDWj/ZnDtu2qOfMxj/AB6V5N47+IEuvafEkrec6zMYQTsZAFUbmA9TyB9a+i9Q0ON5NQN2ymK5Ksw4ycDucc18qfFKytdP8d6pb2QIhUo2OMBiik4/OmCOVldpJHdzlmJYn3NR0rUgpFDR0paQdKWgBaBSUtACjrThSCtzwvop1m4mUbz5Sg7EGS2TQBjjkgAZPtWxa+HdVuADHYXG0jOfLP8AhXtHhP4eWI1JA9lugVSVLg/e45JzXtuk6TZ2sCxxxoSvcCmTc+VNE8MzxE+ZbsCo3NuBDdeuOuK9o+GEsEFtHbvqcsbBtsVtztGSfw5J/Wut8dadajSJrlIVFxCMhlHzEZGR78Vy3hOxjEsN2sBEYIYF8jBycDigR6sWEafMDwBz1zXO65qUUivHZyA3EbDjkEe4/wDrVqeZLLYSPCxdyvy9+a8g8WtqmkavDeuZZoGQBsA8Pg8frQgL+uarc6haS24XEMhHyEHI/vAj61k22p3Fpp9sn70SRblAJOQMcY9gaSwvV1KHz0mMdyD+8UNg5xjdVO81i5achwPlXBJFMDMu9QkednmLliXVj1JBxUusBYdIMU7xrMuXUZ+8uBj8ajv7+1ucM1tEjBcHywQD+tZWpRwzNtSYhscKfpQBjJdq0eNjBwevaqlxI24NGxB9jzUkkDo5+Z8HtVfA385JpDMW8/d3L/LjJzVSNsP6D1rS1mPDJInIxg/nWNvywB6UhlzIVgcnPY+lbk3iAXMNpHI0iKn+tKdTgdvb2rAO5yoUHOKlSzAVSzs3qqr/AFoA9H1fxpZy6Fp0dtqDERIsTxZbIAXBBGPbr71van8QvDV/pyRGaZWtFHk5Z/3ucZDYHTjvXi1zHEjEJGR05Jqrkc+uKdxWO48ReNreSCa00aC4ihfglpyV9eFIH5VzcOrKmowzNE7W6vl4y2S6ZyVz1GQMVk5BJB5q9Z2ksib0gkdevyqSMDrSGfWfwp0uGx0uG/WfzormMfZVXcRHG3O3n36/SvRQeOc18/fB3Wdcgh0e1lgZ9MR5IkzuOwHnpn1PH1r32J/MTdtZTkjBpsRV1O1hu7Z4rhFaJlwQ3TFfOWu/FHW08TSafoUVtZWNqxiVp5CSwUkZ6ZAPoAa+lLqETxNGSQGGDj0rx3xH8II77xbDewXBgs5Im85osiQOSTxzjnj8ulAHoHhnUbjUdFt7mQxSs4BLQklDx7gH9K1obmOSENGSfcCud8N+Fk8PW8arqF7dKH4adySq7QAvXGAR6d66DIiOAyHPGCMUAVtRiM6NwSu0/jxXyz8Z7BNN8WahJKsb/a4VWPa/IIC8kfgK+qNQcLExkYqCO1fM/wAcotEju4xbzStqO5ncbtw5A7mgDyI0hpTSUihopaQUtIApR0pBThTAcK9L+C0c9p4pLTWkpjli25ZCB161wvh6NJtasI5UWSNp0DKwyCM9CK+xoLK1idzFbQIQcArGBxxTQmy7bReQGVIsuOeK0LYkpHJKHjcn7pzViFR85wM56/gKgviQEwSPp9aCTkvFJN3dRrJcPAqyEOgJ+Zfce/8AWqOkW+q2EqxWdobnTZXHzsSSBnqD+fWr3jLh8jgmPn3ro/Bv/Iu2v+6f/QjQBowp5NqhgHT7wP615n8Xbh5ltYoZlWJcO/BJDc/416nIBtbj1rxn4zAJNZlAFJXkjjuaAPPbGSRXOxzuHBArRkbMBdnfc3H1qhpvMi/57VNqjHy1GTjH9KYFaZgMAMCe/UVVeQ+b15qT/lmPwqvcAbQcDPrSAjKsoPPyjsagaJXGclPwNJN3qkPvD60AM1OINbtGgJbtxXPrancpdguf0rp7sAR8DHy9q5s/cNIpF2EqkQwv6daUvjAXAGeT+FVZCdsYzwO1Oh6fjQIpzMWZiSTURyTmlk6U6LlufSgZp6PpYuQZZt3lgOVQA5cqASB+dex/Drw7dFBbyWCKs0LS4ZThBvUhG9CevrgVh/C+NH1/QVdFYee3BGf4BX05bQRRhmjiRWb7xVQCfrTEY3hnwvY6KskttD5dxM3mS/MSM+wPA/CukHTrxTV7/WlXp+NIAPWmMB1yBTz1FM70ARkZ4JFV54VIyeCDkMexqyoyxz6VG/3TTAw9cR4tJn3mWbKnPlg7h9Mc18wfFjQDY3MF0iylnQmQOxLLz3/xr6w1Ti3fHHFfOXxT/wCQdq57qEA9sjmgDxQ9aQe1OamHpSKP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31894=[""].join("\n");
var outline_f31_9_31894=null;
var title_f31_9_31895="Polychromatophilia";
var content_f31_9_31895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polychromatophilia due to increased reticulocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear taken from a patient with increased reticulocytes. Unlike mature red cells (thin black arrows), which have central pallor and are the same size as the nucleus of a small lymphocyte (thick arrow), reticulocytes (blue arrows) are larger, have a blue tint, and lack central pallor because they are not biconcave discs. (Wright-Giemsa stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31895=[""].join("\n");
var outline_f31_9_31895=null;
var title_f31_9_31896="Subcutaneous and intramuscular immune globulin therapy";
var content_f31_9_31896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subcutaneous and intramuscular immune globulin therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/9/31896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/9/31896/contributors\">",
"     Melvin Berger, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/9/31896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/9/31896/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/9/31896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/9/31896/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/9/31896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin may be given by the subcutaneous or intramuscular routes for the treatment of immunodeficiency states and a variety of other disorders. Subcutaneous injections of Ig were originally employed by Bruton in the first patient diagnosed with agammaglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune globulin, intravenous (Human) will be referred to as IVIG in this review, because this term is commonly used by clinicians, although the abbreviation used by industry and various regulatory agencies is IGIV.",
"     </li>",
"     <li>",
"      Immune globulin, subcutaneous will be abbreviated as IGSC or SCIG.",
"     </li>",
"     <li>",
"      Immune globulin, intramuscular will be abbreviated as IM ISG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SCIG has dramatically gained popularity since the demonstration that immune globulin could be given reasonably quickly by battery driven pumps, with relative freedom from the adverse effects often associated with intravenous administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, intramuscular preparations have become less popular with time and are uncommonly used today, except in the form of hyperimmune globulins (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/293?source=see_link\">",
"     tetanus immune globulin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    ) for prophylaxis of certain infectious diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=see_link&amp;anchor=H10#H10\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Hyperimmune globulins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available preparations, dosing, administration, and adverse effects of SCIG and IM ISG will be reviewed here, as these issues apply to the use of immune globulin in antibody deficiency states. Comparisons between the two most common routes of delivery, subcutaneous and intravenous, are also discussed. Intravenous immune globulin is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPARISON WITH IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous administration of immune globulin offers some significant advantages over intravenous administration, whereas IM ISG has few advantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Advantages of SCIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of SCIG, compared to IVIG, include fewer systemic reactions, more consistent serum levels of IgG, and the convenience of home-infusion without the need for venous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous IgG administration is remarkably free from serious or systemic adverse events. Systemic reactions associated with SCIG have been reported in 0 to 3 percent of patients, with most studies reporting rates &lt;1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Systemic reactions'",
"      </a>",
"      below.) For comparison, systemic reaction rates with currently available IVIG preparations range from 2 to 6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, SCIG is tolerated by most patients who had previous serious systemic reactions to IVIG or IMIG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/6\">",
"       6",
"      </a>",
"      ]. The lack of systemic adverse effects is likely related to the relatively slow rate with which SCIG is absorbed from the subcutaneous site(s) into the circulation. The sudden high peak in serum IgG which occurs following IVIG infusion is thus obviated.",
"     </li>",
"     <li>",
"      SCIG provides more even, physiologic serum levels of IgG because it is administered in smaller, more frequent doses, avoiding the low trough levels that occur near the end of the three or four week dosing intervals of IVIG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/7\">",
"       7",
"      </a>",
"      ]. Symptoms that occur towards the end of the longer dosing intervals with IVIG, such as increased fatigue, myalgia, and arthralgia or arthritis, are not usually reported with SCIG.",
"     </li>",
"     <li>",
"      The ability to self-administer SCIG at home improves the patient's sense of autonomy and frees them from the constraints of scheduling infusions in a medical facility. Positive effects of",
"      <span class=\"nowrap\">",
"       home/self",
"      </span>",
"      infusion on health-related quality of life have been documented in several formal studies, in both adults and children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subcutaneous infusions may be particularly useful in patients for whom venous access is problematic, and circumvents the need for implantable venous access devices such as \"ports\" in those patients.",
"     </li>",
"     <li>",
"      SCIG can safely be administered to most patients with IgA deficiency, including those who previously experienced systemic reactions to IVIG. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'IgA deficient patients'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      SCIG does not require premedications in most patients, whereas a significant proportion of patients receiving IVIG do require ongoing premedication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disadvantages of SCIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some parents feel uncomfortable infusing their young children, and adults may not be compliant or may have difficulty with performing infusions consistently for a variety of reasons. The leading complaints about SCIG therapy are the frequency of infusions and the occurrence of local reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/10\">",
"     10",
"    </a>",
"    ]. Changing to an every other week routine can circumvent the first issue for many patients and local reactions improve with time in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disadvantages of IMIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;IM administration of immune globulin can be painful (particularly for children), the amount that can be administered is limited by the volume that can be injected into the muscle, and there is risk of local tissue injury, such as nerve damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cost issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary cost associated with gammaglobulin replacement therapy is the gammaglobulin product itself. All forms of gammaglobulin are expensive, but there are significant differences among health care delivery systems. In most European and Canadian cost analyses, the cost of medications is lower and SCIG is significantly less expensive because it avoids medical facility and nursing costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4,10-13\">",
"     4,10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, where medications are relatively more expensive, the cost differential between IVIG and SCIG administration is smaller, although still usually in favor of SCIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AVAILABLE PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gammaglobulin products specifically intended for subcutaneous and intramuscular administration are more concentrated than those designed for intravenous use in order to reduce the volume that is required to deliver a given amount of IgG. As an example, the amount of IgG in 10 mL of a 10 percent IV product (1 gram) would be delivered in 6.25 mL of a 16 percent IM product, or 5 mL of a 20 percent SC product.",
"   </p>",
"   <p>",
"    Several studies have shown that 10 percent liquid products intended for IV use are also well tolerated by the SC route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], and three 10 percent IVIG products marketed in the US have been approved by the FDA for SC use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Subcutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States (US), available products include 10 percent Gammagard, 10 percent Gamunex-C, 10 percent Gammaked, and 20 percent Hizentra solutions (",
"    <a class=\"graphic graphic_table graphicRef59390 \" href=\"mobipreview.htm?41/59/42940\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/18\">",
"     18",
"    </a>",
"    ]. Several additional products are available in the European Union (EU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/15,19\">",
"     15,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intramuscular",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small supply of 16 percent Immune Serum Globulin (ISG) for IM administration is available in the form of GammaSTAN",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    (Grifols, Inc.) (",
"    <a class=\"graphic graphic_table graphicRef59390 \" href=\"mobipreview.htm?41/59/42940\">",
"     table 1",
"    </a>",
"    ). The purification process used for IM ISG and the",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    treatment provide levels of safety from transmission of blood-borne infections comparable to that of many IV and SC preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IM ISG injections are generally used only in single doses or to provide short-term treatment. Examples of situations in which IM ISG might be used include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A local outbreak of measles or another infectious disease against which certain individuals had not been immunized. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22793?source=see_link&amp;anchor=H13#H13\">",
"       \"Prevention and treatment of measles\", section on 'Use of immune globulin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IM ISG was formerly used routinely to prevent hepatitis A infection in individuals traveling to endemic areas. However, it is less often used for this purpose since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"       hepatitis A vaccine",
"      </a>",
"      became available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link&amp;anchor=H20#H20\">",
"       \"Hepatitis A virus vaccination and postexposure prophylaxis\", section on 'Postexposure prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The usual dose of IM ISG in such situations would be 0.02",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    if the period of exposure will be less than three months, and 0.06",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    if the exposure will be three months or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/20\">",
"     20",
"    </a>",
"    ]. These doses may be repeated every four to six months as necessary. Multiple injection sites should be used if greater than 10 mL of IM ISG are to be administered at one time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     STUDIES OF EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple prospective trials, including both children and adults, have demonstrated that SCIG is as effective as IVIG in protecting patients with primary immune deficiency from infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In addition, a randomized crossover trial directly compared the two forms of therapy in 40 patients with primary antibody deficiencies and found no statistically significant difference in the number of infections reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/23\">",
"     23",
"    </a>",
"    ]. An analysis of pooled data (from seven studies of four different SC products from three different manufacturers) showed that the incidence of infection decreases linearly with increased steady state IgG levels on SCIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/24\">",
"     24",
"    </a>",
"    ]. Because IM ISG is rarely used for chronic therapy, there have been no studies comparing IM administration to other routes for more than 20 years.",
"   </p>",
"   <p>",
"    The efficacy of IVIG, compared to no treatment, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link&amp;anchor=H7#H7\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Efficacy in preventing infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADMINISTRATION AND DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients can be readily trained to infuse SCIG themselves at home, or parents may administer the infusions to their children. This appears to be true in the elderly (&gt;65 years of age) and very elderly (&gt;75 years) as well, including those on anticoagulant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    platelet inhibitor therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/25\">",
"     25",
"    </a>",
"    ]. Reliability of the patient is an important consideration in selecting those to whom self-administration at home should be offered. Patients infusing at home should keep records of the lot numbers of all individual products they administer and should continue regular follow-up with the prescribing clinician. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication is usually not required with SCIG, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or other antihistamines may prevent or reduce local injection site reactions in those patients who develop them with initial infusions. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Local reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children may prefer application of a local anesthetic cream like EMLA to the site at which the needle will be inserted. (See",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/43/34486?source=see_link\">",
"     \"Lidocaine and prilocaine: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dose and frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with IVIG, SCIG is administered in smaller doses and given more frequently. An empiric starting dose for SCIG is 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week, for both adults and children.",
"   </p>",
"   <p>",
"    Doses should be rounded to the nearest full vial of drug to avoid wastage. Another approach to avoid wasting drug involves adjusting the dose up or down slightly on alternate weeks. As an example, if the drug is supplied in 10 mL vials, a patient requiring 45 mL per week could alternate between 40 mL one week and 50 mL the next [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Alternative schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIG can also be administered at a dose of 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/14\">",
"     14",
"    </a>",
"    ], or in doses less than 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given more than once a week. However, these alternative schedules are not in the US FDA-approved labeling for currently available products. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Rapid push administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Initiating therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following infusion, SCIG is absorbed from the subcutaneous space over several hours. Peak serum levels occur two to three days later. Subcutaneous administration avoids the high peaks and low troughs that result from less frequent IV boluses, resulting in more even serum IgG concentrations over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Advantages of SCIG'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Therapeutic plasma levels are not attained as rapidly with SCIG, compared with IVIG. To address this issue, patients newly starting SCIG can be given a single loading dose of IGIV, and then switched within seven days to a subcutaneous product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/21\">",
"     21",
"    </a>",
"    ]. An alternative method is to load the patient by giving five doses, each equivalent to the planned weekly dose, on consecutive days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/26\">",
"     26",
"    </a>",
"    ]. This practice often facilitates education of the",
"    <span class=\"nowrap\">",
"     patient/parent",
"    </span>",
"    in the proper technique for SC infusion. With loading, steady state is achieved within one week. Without loading, steady state with weekly infusions is reached after about six to ten weeks of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Conversion from IGIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;To convert a patient from IV to subcutaneous dosing, the same total monthly dose that has been given IV is usually divided by four and that amount is given weekly. This approach will, after several months, result in steady-state levels of IgG that are approximately 10 to 20 percent higher than those achieved with an identical dose of IV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/27\">",
"     27",
"    </a>",
"    ]. Alternatively, 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week may be a good starting dose for most patients (adults and children).",
"   </p>",
"   <p>",
"    Immune globulin given by the subcutaneous route may have lower bioavailability than by the intravenous route; this is primarily reflected in truncation of the peak IgG levels which would be achieved just after a large IV dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/1,7,27,28\">",
"     1,7,27,28",
"    </a>",
"    ]. The decreased area under the peak with SCIG as compared to IV is not totally equaled by the increase in the &ldquo;trough&rdquo; with SCIG as compared to IVIG. Thus, the total monthly dose of SCIG required to give the same area under the curve (AUC) of serum IgG over time is 1.37 to 1.53 times the dose of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/16-18,21,27-29\">",
"     16-18,21,27-29",
"    </a>",
"    ]. It is not clear to what extent this may reflect inclusion of time points before the IgG has equilibrated between the intra- and extravascular spaces, local degradation within the tissues,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other factors. In the US, the FDA has required that a \"dose adjustment\" be included in the labeling of SCIG products, but regulatory authorities in Europe require only that IgG trough levels on new SCIG products be comparable to those achieved with the same monthly dose of IV or other licensed SCIG products. There has been no head-to-head comparison of the efficacy of matching AUCs rather than IgG trough levels, and studies using 1:1 dosing regimens in Europe have shown very similar incidences of infection as US studies of the same products using the \"dose adjustments\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/16-18,21,24\">",
"     16-18,21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More important, a variety of studies suggest that different patients require different serum IgG levels to remain infection-free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Therefore, each patient's dosing regimen should be individualized to a level that keeps the patient relatively infection-free.",
"   </p>",
"   <p>",
"    Obese patients (Body Mass Index &gt;30) required higher doses of SCIG to achieve AUCs equal to those they attained previously with IVIG in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this has not been reported in other studies. Since bioavailability of SCIG may be decreased in obese individuals, serum IgG levels should be monitored and doses adjusted as necessary to achieve satisfactory protection from infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Technique and equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients use battery- or spring-driven pumps to deliver their weekly dose over about two hours. During the infusion, the patients can ambulate and go about normal, non-strenuous activities. Infusion sites are prepared by wiping with alcohol or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    . Extensive scrubbing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    povidone-iodine is not required. After an infusion, a simple adhesive bandage strip may be put over the puncture site, although no covering is needed in many cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pump administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 5 and 30 mL can be infused at a given site, depending upon the patient's body habitus, age, and previous experience with the particular product being used. Patients requiring larger volumes should infuse at multiple sites simultaneously. Tubing sets with two or more bifurcations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of multiple pumps simultaneously facilitates infusion into several sites. For most adults, infusions of 40 mL are conveniently given over approximately two hours, by using two sites simultaneously. Patients who tolerate infusion rates of 20",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    can try increasing to 40",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    to reduce the overall time required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/32\">",
"     32",
"    </a>",
"    ]. The maximum rate approved by the US FDA is 50",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    given into several sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/29\">",
"     29",
"    </a>",
"    ]. Some patients who require large volumes of IgG may choose to divide the total volume into separate infusions to be given on different days.",
"   </p>",
"   <p>",
"    Syringe driver pumps, such as the \"Freedom 60\" (Repro-Med Systems, Inc, Chester, NY), with 40 to 60 mL syringes are convenient for this type of infusion, while smaller battery operated pumps are easily used for administering 10 to 20 mL infusions of the 16 percent preparations (1.6 to 3.2 grams, respectively) in children.",
"   </p>",
"   <p>",
"    Infusion sites should be on the lower abdomen,",
"    <span class=\"nowrap\">",
"     upper/outer",
"    </span>",
"    thighs, or backs of the arms. The tip of the infusion needle should be inserted 1 to 1.5 cm into the subcutaneous tissue. Butterfly&reg; or \"Soft-set\" needles are commonly used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/33\">",
"     33",
"    </a>",
"    ]. Shorter needles may be needed for very lean patients and young children. However, inadvertent intradermal infusion should be avoided, and patients who complain of local site reactions often do better with longer, rather than shorter, needles.",
"   </p>",
"   <p>",
"    Patients should be trained to make sure that the infusion needle has not accidentally been placed in a blood vessel, as inadvertent intravascular administration of SCIG preparations could increase the risk of systemic reactions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombotic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4\">",
"     4",
"    </a>",
"    ]. A two step check for blood return in the infusion line is suggested. The patient (first) pulls back on the syringe and checks for blood return and (second) removes the syringe from the infusion set and waits for 15 seconds before proceeding, to assure that no blood appears in the line [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rapid push administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIG can also be self-administered without a pump, using a \"rapid push\" method. This is accomplished with standard, disposable 10 or 20 mL syringes and Butterfly needles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/34\">",
"     34",
"    </a>",
"    ]. In one study of 104 patients, the rapid push method was preferred by the majority of patients beginning SCIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/34\">",
"     34",
"    </a>",
"    ]. Subjects were given information about administration with pumps versus rapid push, and 71 percent chose rapid push. Patients self-administer 3 to 20 mL, usually at one site, three times weekly, on average. One-third experienced local reactions. Only two patients later changed to pump delivery. Therefore, this may represent another practical method of delivery, with the advantages of less equipment, decreased expense, and more rapid administration.",
"   </p>",
"   <p>",
"    Regardless of the technique used, patients should be instructed in proper disposal of needles and other medical waste, and they should be given proper disposal containers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Target serum levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum IgG levels can be drawn at any time relative to infusions with SCIG, once steady state has been reached, which is usually after 6 to 10 weeks of SCIG therapy. The concept of a &ldquo;trough level&rdquo; is not applicable, since serum levels remain relatively constant. Serum levels are useful in assessing the adequacy of a given SCIG dose. However, the patient's clinical condition should be the main determinant of the necessary IgG level, and multiple studies show that different patients require very different IgG levels to remain infection-free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Initiating therapy'",
"    </a>",
"    above.) Several studies confirm the clinical impression that higher serum IgG levels are associated with increased freedom from infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/24,31,35\">",
"     24,31,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of immune globulin required to achieve and maintain a desired level depends upon the patient's initial IgG concentration, the frequency of administration, and the half-life within that particular patient. Some patients appear to metabolize or lose immune globulin more rapidly than others, and some require more to remain protected from infections. The reasons for these individual differences are unknown. Increased catabolism can also be seen when patients are infected or under physiologic stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Optimizing the dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graphing the patient's serum IgG levels over time and noting when infections occur has been suggested as a means of determining the optimal dose for a given individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/30\">",
"     30",
"    </a>",
"    ]. Some patients reportedly demonstrate a threshold level, above which the incidence of infections dramatically decreases. The weekly IgG dose may be increased in increments of 10 to 20 percent, or one extra dose per month may be added. Six to eight weeks should be sufficient to determine the amount by which an incremented weekly dose has raised the steady state serum IgG level, but several months may be necessary to assure that the desired clinical efficacy has been achieved. A pooled analysis of several SCIG studies suggests that maintaining higher steady-state IgG levels results in fewer infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with chronic infections, the optimal dose of IgG can also be assessed by following the white blood cell count",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory indicators of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation, such as the erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the C-reactive protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Patients with normal pretreatment IgG levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with normal or elevated total IgG levels and specific antibody deficiency cannot be monitored simply by checking serum levels. Instead, the patient should keep careful records of the dose of SCIG and any infections, and this should be reviewed regularly with the clinician to determine the dose which successfully reduces the incidence and severity of infections for that individual.",
"   </p>",
"   <p>",
"    Examples of disorders with normal or high total IgG levels include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deficient responses to certain types of antigens, such as bacterial polysaccharide antigens",
"     </li>",
"     <li>",
"      Deficiency of one or more specific subclasses of IgG with demonstration of impaired vaccine responses",
"     </li>",
"     <li>",
"      Specific antibody deficiency co-existing with monoclonal gammopathy or polyclonal B-cell activation (ie, due to systemic lupus erythematosus, EBV infection, or EBV-induced lymphoproliferative disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with such disorders may actually require higher doses of immune globulin because they may have accelerated catabolism of the administered antibodies. Increased catabolism can also be seen when patients are infected or under physiologic stress, as mentioned previously.",
"   </p>",
"   <p>",
"    Another technique for assessing adequacy of treatment in such patients is the measurement of antibodies against specific pathogens (eg, pneumococcal polysaccharides",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    measles), to assure that protective levels are maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monitoring for blood borne illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring for development of blood-borne infections is recommended every 6 to 12 months. Although all currently licensed products are believed to be safe from transmission of known blood-borne infections, past experiences with hepatitis C transmission due to contaminated IGIV, and occasional recalls of blood products due to the retrospective diagnosis of Creutzfeldt-Jacob disease in donors, make it clear that the risk is always present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=see_link&amp;anchor=H30#H30\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Risk of transmission of blood borne pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lot number, expiration date, and manufacturer of any blood product infused into any patient should be carefully recorded. Patients should be encouraged to keep their own logs for this purpose, in addition to documentation in the medical record. Several manufacturers of immune globulin provide specialized logbooks for this purpose, which also allow the patient to record adverse effects and significant infections. There are also some internet- or computer-based recording systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SAFETY AND ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, SCIG has many fewer systemic side effects than IVIG. IMIG, on the other hand, is associated with significant local pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fainting, and is less tolerable overall than either IVIG or SCIG for more than occasional use. The rest of the discussion in this section applies to SCIG only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     IgA deficient patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIG may be administered to most IgA-deficient patients, although caution should always be used in patients who might be at risk for development of anti-IgA antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/36\">",
"     36",
"    </a>",
"    ]. Anaphylaxis due to IgA in currently available subcutaneous products has not been reported, and some studies suggest that subcutaneous infusions might actually induce tolerance to IgA in previously sensitized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Initial infusions in IgA deficiency patients should be given slowly, under observation, in a clinic or office setting. Clinicians in the US sometimes prescribe epinephrine autoinjectors for patients who infuse at home, although these are rarely needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients experience some degree of local swelling at the infusion site(s), which may decrease in severity or frequency after the first few infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/22\">",
"     22",
"    </a>",
"    ]. Redness, burning,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    itching are also common. These reactions usually clear within 12 to 24 hours, as the drug is absorbed from the subcutaneous depot.",
"   </p>",
"   <p>",
"    Local reactions often subside after 8 to 10 weeks of therapy. In one study of 32 patients self-infusing SCIG, the percentage of subjects experiencing transient local swelling declined from 75 percent at week 1, to 25 percent at week 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/22\">",
"     22",
"    </a>",
"    ]. It is recommended that patients rotate infusion sites, although no long-term pathology has been reported at sites that are used repeatedly. Treatment of local site reactions is not usually required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported rates of systemic adverse reactions associated with subcutaneous infusions are &le; 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/1,21-23\">",
"     1,21-23",
"    </a>",
"    ]. In one review of 10 series including &gt;55,000 infusions, the rate of systemic reactions was &lt;1 percent in eight of the studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4\">",
"     4",
"    </a>",
"    ]. Life-threatening anaphylactic reactions have",
"    <strong>",
"     not",
"    </strong>",
"    been reported with SCIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3071252\">",
"    <span class=\"h2\">",
"     Risk of thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic events have been reported with IVIG, as well as with some forms of SCIG. The overall incidence of thromboembolic events seems lower with SCIG than with IVIG, but inadvertent injection of concentrated SCIG preparations directly into blood vessels may increase this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIG has been safely used in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. However, these products are currently labeled as category C drugs because human and animal data are limited.",
"   </p>",
"   <p>",
"    The maintenance of normal serum immunoglobulin levels in pregnant women with primary immune deficiencies may have important benefits for both mother and fetus. Early exposure to maternal IgG is believed to influence the developing immune system of the fetus, and the impact of maternal immunoglobulin deficiency on the fetus in the absence of replacement therapy is not fully understood. In addition, the presence of normal immunoglobulin levels protects the mother through pregnancy and the peripartum period, and provides protective antibody for the newborn, which is especially important because adequate IgG production in the baby is not usually achieved until six months of age. Since most of the IgG present in the newborn is transferred transplacentally during the third trimester, pre-term babies may have very low IgG levels, putting them at increased risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/12/16585?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunity of the newborn\", section on 'B cells and immunoglobulins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose during pregnancy should be increased as the mother gains weight, to ensure that serum IgG levels are adequate and that there is sufficient IgG for transfer across the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31896/abstract/38,40\">",
"     38,40",
"    </a>",
"    ]. We suggest measuring IgG levels at least monthly starting in the second trimester, and perhaps every second week or even weekly in the third trimester as the due date approaches. Until more data are available, it is reasonable to keep the mother's IgG level within &plusmn;10 percent of the level at which she was maintained before the pregnancy, assuming she was free from infection at that level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous immune globulin (SCIG) offers several advantages over intravenous immune globulin (IVIG): it causes fewer systemic reactions, provides more consistent serum levels of IgG, and can be infused by patients at home, leading to improved quality of life. In contrast, intramuscular immune globulin (IMIG) has few advantages compared with IVIG or SCIG, and is rarely used for long-term therapy in immune deficiency. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Comparison with IVIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune globulin products specifically intended for subcutaneous and intramuscular administration are generally more concentrated than those designed for intravenous use, allowing more immune globulin to be administered in lower volumes. Three 10 percent IVIG products have been approved for SC administration as well (",
"      <a class=\"graphic graphic_table graphicRef59390 \" href=\"mobipreview.htm?41/59/42940\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Available products'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subcutaneous immune globulin (SCIG) is as effective as intravenous immune globulin (IVIG) in preventing infections in patients with primary antibody deficiencies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Studies of effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCIG is usually given in smaller doses at weekly intervals, although there are other schedules that may be preferable for certain patients. To convert a patient from IGIV to IGSC, the total monthly IV dose is divided by four and that amount is given subcutaneously each week. An increment of 37 to 53 percent of the monthly IV dose is recommended if it is desired to achieve an area under the curve of serum IgG level versus time on SCIG equal to that of previous IVIG therapy. Alternatively, 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week is a good starting dose for both adults and children. Steady state therapeutic levels can be reached within one week if loading doses (either one IV dose or multiple SC doses) are given. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Administration and dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common adverse effect is local swelling at the site of infusion, which occurs at least initially in the majority of patients. Local swelling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      redness usually lasts less than 12 to 24 hours and these reactions usually decrease in frequency and severity after the first two months of therapy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Safety and adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. Berger is Senior Medical Director, Immunology Research and Development, CSL-Behring, LLC., King of Prussia, PA, manufacturer of Carimune NF, Privigen, and Hizentra. The section editor of the topic, E. Richard Stiehm, MD has no financial interests in the therapies discussed in the review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/1\">",
"      Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/2\">",
"      Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 2008; 101:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/3\">",
"      Fasth A, Nystr&ouml;m J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/4\">",
"      Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/5\">",
"      Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/6\">",
"      Gardulf A, Hammarstr&ouml;m L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/7\">",
"      Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/8\">",
"      Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/9\">",
"      Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/10\">",
"      H&ouml;gy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/11\">",
"      Beaut&eacute; J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol 2010; 160:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/12\">",
"      Maroto Hernando M, Soler Palac&iacute;n P, Martin Nalda N, et al. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain]. An Pediatr (Barc) 2009; 70:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/13\">",
"      Ducruet T, Levasseur MC, Des Roches A, et al. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol 2013; 131:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/14\">",
"      Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/15\">",
"      Radinsky S, Bonagura VR. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 2003; 112:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/16\">",
"      Wasserman RL, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010; 161:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/17\">",
"      Schiff R, Leibl H, Wasserman R, et al. IGIV-10% infused intravenously and subcutaneously to subjects with primary immunodeficiency diseases. Efficacy, tolerability and pharmacokinetic comparison. Clin Immunol 2010; 135:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/18\">",
"      Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/19\">",
"      Quinti I, Pierdominici M, Marziali M, et al. European surveillance of immunoglobulin safety--results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002; 104:231.",
"     </a>",
"    </li>",
"    <li>",
"     GammaStan S/D Prescribing Information, Talecris Biotherapeutics, Inc. Research Triangle Park USA, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/21\">",
"      Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/22\">",
"      Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. J Clin Immunol 2006; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/23\">",
"      Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/24\">",
"      Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol 2011; 31:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/25\">",
"      Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med 2011; 123:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/26\">",
"      Waniewski J, Gardulf A, Hammarstr&ouml;m L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/27\">",
"      Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/28\">",
"      Bonilla FA. IgG replacement therapy, no size fits all. Clin Immunol 2011; 139:107.",
"     </a>",
"    </li>",
"    <li>",
"     Hizentra Prescribing Information, CSL-Behring LLC, King of Prussia, PA, USA 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/30\">",
"      Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/31\">",
"      Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/32\">",
"      Gardulf A, Hansen S, Johansson K, et al. Rapid subcutaneous IgG replacement therapy in children and adults: 20 years of clinical experience. Immunologia 2006; 24:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/33\">",
"      Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/34\">",
"      Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010; 30:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/35\">",
"      Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010; 137:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/36\">",
"      Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003; 61:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/37\">",
"      Sundin U, Nava S, Hammarstr&ouml;m L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/38\">",
"      Berger M, Cupps TR, Fauci AS. High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy. JAMA 1982; 247:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/39\">",
"      Gardulf A, Andersson E, Lindqvist M, et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 2001; 21:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31896/abstract/40\">",
"      Hansen S, Gardulf A, Andersson E, et al. Women with primary antibody deficiencies requiring IgG replacement therapy: their perception of prenatal care during pregnancy. J Obstet Gynecol Neonatal Nurs 2004; 33:604.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3942 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31896=[""].join("\n");
var outline_f31_9_31896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPARISON WITH IVIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Advantages of SCIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disadvantages of SCIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disadvantages of IMIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cost issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AVAILABLE PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Subcutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intramuscular",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      STUDIES OF EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADMINISTRATION AND DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dose and frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Alternative schedules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Initiating therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Conversion from IGIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Technique and equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pump administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rapid push administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Target serum levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Optimizing the dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Patients with normal pretreatment IgG levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monitoring for blood borne illnesses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SAFETY AND ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      IgA deficient patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Local reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3071252\">",
"      Risk of thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/59/42940\" title=\"table 1\">",
"      Brands Ig for SQ IM use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/12/16585?source=related_link\">",
"      Immunity of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/43/34486?source=related_link\">",
"      Lidocaine and prilocaine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22793?source=related_link\">",
"      Prevention and treatment of measles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_9_31897="Nephrology pattern 14";
var content_f31_9_31897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 14",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31897=[""].join("\n");
var outline_f31_9_31897=null;
var title_f31_9_31898="Treatment of minimal change disease in adults";
var content_f31_9_31898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of minimal change disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/9/31898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/9/31898/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/9/31898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/9/31898/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/9/31898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/9/31898/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/9/31898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy is the treatment of choice in minimal change disease (MCD), leading to complete remission of proteinuria in over 85 to 90 percent of cases. This approach is based upon the beneficial results reported in several large prospective randomized trials in children, extensive observational studies in children and adults, and a very limited number of small randomized controlled trials in adults that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    with no specific therapy or that compared various prednisone regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Due to their small size, the results of these controlled trials are not definitive.",
"   </p>",
"   <p>",
"    Minimal change disease accounts for 90 percent of cases of the idiopathic nephrotic syndrome in young children (under age six) and 65 percent of cases in older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. As a result, glucocorticoid therapy is usually begun empirically in children and a kidney biopsy is performed only for glucocorticoid-resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, MCD accounts for only 10 to 25 percent of cases of nephrotic syndrome in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Thus, patients over age 16 are generally treated after kidney biopsy that shows MCD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children tend to remit rapidly, with 50 percent responding within two weeks and almost all within eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. Adults tend to respond more slowly, with more than 25 percent of responders taking three to four months or longer to undergo complete remission (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Therefore the definition of steroid resistance is not the same for patients younger than about 16 years of age and for those over about 17.",
"   </p>",
"   <p>",
"    The treatment of MCD in adults will be reviewed here. The treatment of other frequent causes of the nephrotic syndrome occurring in adults, such as focal segmental glomerulosclerosis (FSGS), membranous nephropathy, and primary amyloidosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of therapy must be considered in relation to the natural history of the disease. Historically, untreated idiopathic MCD was associated with a risk of mortality due to infection and thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data suggest that the rate of spontaneous early remission (eg, within a few months) in adults is approximately 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2,14,18\">",
"     2,14,18",
"    </a>",
"    ]. In addition, a substantial proportion of untreated patients eventually undergo remission after a prolonged period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. In a series of 51 patients, 33 percent had a spontaneous remission at some time during the disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ]. This was illustrated in the only available randomized controlled trial that, in 1970, compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    versus no specific therapy and included 31 patients with MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2\">",
"     2",
"    </a>",
"    ]. Remission of proteinuria to less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in the control group occurred in 50 percent by 18 months and approximately 70 percent at three years. This may suggest that the chief benefit of glucocorticoid is to induce and maintain remission until the poorly understood process responsible for MCD abates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KIDNEY FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many patients with MCD have a modest decrease in the glomerular filtration rate during the nephrotic phase, this may be represent \"functional renal insufficiency\" as kidney function returns to normal following resolution of the nephrotic syndrome, even after multiple relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12-14,16,18\">",
"     12-14,16,18",
"    </a>",
"    ]. In a series of 51 patients, 61 percent had higher than normal serum creatinine values when patients were actively nephrotic but renal function returned to normal when remission was achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ]. The nephrotic syndrome may also be associated with a rise in blood pressure over pre-nephrotic baseline levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute kidney failure can occur in idiopathic MCD, and sometimes the glomerular filtration rate does not fully recover to baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14\">",
"     14",
"    </a>",
"    ]. This complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    End-stage renal disease is rare, and has only been reported in steroid-resistant cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14,19\">",
"     14,19",
"    </a>",
"    ]. However, FSGS is often seen on a late kidney biopsy in patients with glucocorticoid-resistant disease and in all patients who develop progressive renal failure. Whether this represents sampling error on the initial kidney biopsy due to the focal nature of FSGS, or true progression from MCD to FSGS is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of treated MCD is favorable, with the great majority of patients eventually attaining complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/11,19,20\">",
"     11,19,20",
"    </a>",
"    ]. The most important prognostic factor appears to be the initial response to corticosteroid therapy.",
"   </p>",
"   <p>",
"    The classification of response to therapy is based upon the relative reduction in proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,21\">",
"     12,21",
"    </a>",
"    ]. The following are commonly used definitions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete response (remission) is a reduction in proteinuria to 300",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      A partial response is a reduction in proteinuria of 50 percent, with absolute values between 300 mg and 3.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      Another study defined partial remission as proteinuria less than 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      with a normal serum albumin concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"       16",
"      </a>",
"      ]. We feel that partial remission lasting more than one or two weeks is an unusual event in MCD, occurring in only 2 of 51 patients in the latter study. Furthermore, one can never be certain that such partial responders do not actually have FSGS that was missed on kidney biopsy since MCD is almost always an all-or-none disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A relapse is return of proteinuria to approximately 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in patients who had previously undergone a complete or partial remission. Patients are considered frequent relapsers if they have three or more relapses per year.",
"     </li>",
"     <li>",
"      Glucocorticoid-dependence refers to relapse while on therapy or requirement for continuation of steroids to maintain remission",
"     </li>",
"     <li>",
"      Glucocorticoid-resistance refers to little or no reduction in proteinuria after 16 weeks of adequate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy, or to the rare patients who have some reduction in proteinuria with more prolonged therapy but do not meet the criteria for partial remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoid therapy leads to complete remission in 80 to over 95 percent of adults with MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2,12-16,18,21\">",
"     2,12-16,18,21",
"    </a>",
"    ]. The time course to a complete remission is prolonged, with 50 percent responding by four weeks and 10 to 25 percent requiring more than three to four months of therapy (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2,14-16,18\">",
"     2,14-16,18",
"    </a>",
"    ]. In contrast, most children will respond within four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 to 75 percent of glucocorticoid-responsive adults will have a relapse, and frequent relapses occur in 10 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14,16,18\">",
"     14,16,18",
"    </a>",
"    ]. Steroid-dependence is seen in 25 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Remissions are typically abrupt, with the patient being free of proteinuria within one to two weeks from the time of initial response. In a majority of cases, response to therapy of nephrotic MCD is of an \"all or nothing\" type. Partial responses are not characteristic of MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ] and, when seen, one should suspect a possible misdiagnosis, most often FSGS that was missed by sampling error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/23\">",
"     23",
"    </a>",
"    ]. An exception is the \"tip Lesion\" variant of FSGS, whose response to steroid treatment is comparable to that of MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Tip variant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most relapses occur within one year after glucocorticoid therapy has been tapered or discontinued, although occasional patients have a glucocorticoid-responsive relapse after as long as 25 years in remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,14,25\">",
"     12,14,25",
"    </a>",
"    ]. Relapses may be triggered by allergies or infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with MCD are edematous and often hypertensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. First-line therapy is a salt-free diet and diuretics for fluid removal. If antihypertensive therapy is still required, use of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) seems a reasonable option for blood pressure reduction, and may have the added benefit of reducing urinary protein excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/26\">",
"     26",
"    </a>",
"    ]. Calcium channel antagonists are not a good option as lower limb edema stands among their own side effects.",
"   </p>",
"   <p>",
"    ACE inhibitors or ARBs to prevent progression or statin therapy for hyperlipidemia are not required in normotensive glucocorticoid-sensitive MCD. However, these and other nonimmunosuppressive therapies are warranted in the rare patients with persistent nephrotic syndrome despite immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Persistent nephrotic syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445388988\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445388995\">",
"    <span class=\"h3\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids may have a specific, beneficial antiproteinuric effect on the glomerular filtration barrier in addition to their immunosuppressive effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mainstay of initial therapy of minimal change disease is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , with a large percentage of adults, particularly younger patients, achieving complete remission within a few months (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    ). Approximately 7 to 12 percent of adults with MCD do not respond to initial glucocorticoid therapy and are considered to have resistant disease. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Glucocorticoid-resistant MCD'",
"    </a>",
"    below.) The recommendation for initial therapy with prednisone in adults is based upon the beneficial results reported in several large prospective randomized trials in children, extensive observational studies in children and adults, and a single randomized controlled trial published in 1970 that compared prednisone with no specific therapy among 31 adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this randomized trial, over 75 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -treated patients had remission of proteinuria to less than 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    within six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2\">",
"     2",
"    </a>",
"    ]. By comparison, only 50 percent of those in the untreated group were in remission at 18 months and approximately 70 percent at three years. There are no randomized trials comparing prednisone to other agents for the initial therapy of idiopathic MCD in adults.",
"   </p>",
"   <p>",
"    Although 5 to 10 percent spontaneously remitted within three months in the untreated group in the randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2\">",
"     2",
"    </a>",
"    ], we do not recommend withholding glucocorticoid therapy in an attempt to identify such patients. Such an approach exposes patients to the hazards of persistent nephrotic syndrome and, in an older study in children, was associated with appreciable mortality from infection and thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted in several large prospective trials, almost all children (95 percent or more) with MCD respond to corticosteroid therapy (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, numerous retrospective observational studies have demonstrated a high response rate in patients treated with relatively long courses of high dose daily or alternate day steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/1,12-14,16,18,21,29-31\">",
"     1,12-14,16,18,21,29-31",
"    </a>",
"    ]. The following summarizes the initial therapy, glucocorticoid taper, and relevant results of some of the larger series in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 57 patients (mean age 38 years) treated initially with 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , 58 and 67 percent achieved a complete remission within four and eight weeks, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14\">",
"       14",
"      </a>",
"      ]. An additional nine patients (15 percent) subsequently entered a complete remission with continuation of high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , whereas six (10 percent) remitted following the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . The remaining three patients had a partial remission that may have reflected underlying FSGS. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      After attaining remission, prednisolone was tapered by 5 to 10",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      until reaching 5",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      this dose was continued for a mean of 2.5 years. Relapses occurred in 62 percent, with most occurring during the first 6 to 12 months. Prednisolone alone at a reduced dose (20 to 30",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      successfully treated relapses in 75 percent.",
"     </li>",
"     <li>",
"      One retrospective observational study of 88 patients (mean age 45 years) reported similar efficacy with daily steroids (initial dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, 65 patients) and alternate day steroids (initial dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day, 23 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/21\">",
"       21",
"      </a>",
"      ]. There was no difference in the incidence of remissions (76 and 74 percent for daily and alternate day groups, respectively), time to remission (11 and 16 weeks), relapse rate (75 and 62 percent), or time to relapse (20 and 26 weeks).",
"      <br/>",
"      <br/>",
"      For daily therapy, the time when the taper was initiated and the exact glucocorticoid taper regimen were not specified, but gradual glucocorticoid withdrawal occurred for a total duration of therapy of 26 weeks. With alternate day therapy, steroids were administered initially at 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day for six to eight weeks, then decreased by 20 mg at two week intervals until 40 mg every other day was reached; this was followed by a slower taper based upon clinical response. The total duration of steroid therapy was 29 weeks for the alternate-day steroid group. Interestingly, the side effect profile was similar in the two groups of patients.",
"     </li>",
"     <li>",
"      A study of 50 Chinese patients compared glucocorticoid responsiveness in 35 younger (mean age 39 years) and 15 older adults (mean age 70 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/18\">",
"       18",
"      </a>",
"      ]. After 4, 8, and 16 weeks of glucocorticoid therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      0.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), complete remission was observed in 63, 88, and 94 percent of the younger patients, and 45, 91, and 100 percent of the older patients, respectively.",
"      <br/>",
"      <br/>",
"      The glucocorticoid taper was not specified, but glucocorticoid withdrawal was considered after remission was maintained for three months. The median duration of glucocorticoid therapy was approximately one year and 30 percent were considered glucocorticoid-dependent.",
"      <br/>",
"      <br/>",
"      Relapses occurred in 54 percent during six years of follow-up, with the median time to first relapse being approximately two years. Relapses were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or levamisole; the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      during relapses was not reported.",
"     </li>",
"     <li>",
"      Among 58 adults (mean age 27 years) treated with alternate day steroids (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , maximum 120 mg every other day), 82 and 92 percent of patients were in complete remission by 6 and 12 weeks of therapy, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/30\">",
"       30",
"      </a>",
"      ]. Steroids were then tapered by 10 mg each week, for a total duration of therapy of 18 to 24 weeks. Relapses occurred in 30 percent of patients during a follow-up of three years, which responded to re-treatment with a similar course of steroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Time course and patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course of attaining complete remission in adults is shown in this figure (",
"    <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"     figure 1",
"    </a>",
"    ). The rate of response but not the likelihood of response is influenced by patient age. This was illustrated in a study of 40 adults with MCD, 20 of whom were below age 40; all patients were treated with daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one to three months, followed by gradual tapering over a period of months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/15\">",
"     15",
"    </a>",
"    ]. These patients compared to those over age 40 were much more likely to attain complete remission within eight weeks (73 versus 32 percent). However, the total rate of complete remission was similar in the two groups (88 and 94 percent).",
"   </p>",
"   <p>",
"    Similar findings were noted in the Chinese study cited above: patients with a mean age of 39 were more likely to achieve remission at four weeks compared with those with a mean age of 70 years (63 versus 45 percent), but there was no difference in remission rates at 8 and 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who go into remission typically do so within one to two weeks after the proteinuria starts to decline. This is similar to the typically abrupt onset of nephrotic syndrome in MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/32\">",
"     32",
"    </a>",
"    ]. Interestingly, the natriuresis and loss of edema at the onset of response begin before the serum albumin has begun to rise, indicating that factors other than hypoalbuminemia must contribute to the edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Initial regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available in adults comparing one glucocorticoid regimen to another (eg, daily versus alternate day therapy, oral regimen versus intravenous pulse therapy, short versus long duration). The optimal initial treatment regimen is unclear as the few randomized trials and multiple observational studies most commonly used different regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/4,5,34,35\">",
"     4,5,34,35",
"    </a>",
"    ]. We will present two regimens.",
"   </p>",
"   <p>",
"    Our typical initial regimen in adults is oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a daily dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of body weight (maximum dose 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12-14,18\">",
"     12-14,18",
"    </a>",
"    ]. Daily therapy is usually given as a single dose upon awakening (usually between seven and nine AM) in an attempt to minimize adrenal suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/36\">",
"     36",
"    </a>",
"    ]. We continue the initial dose for a minimum of eight weeks, even in patients who have attained complete remission before that time in an attempt to reduce the rate of relapse. For patients who respond later than eight weeks, prednisone tapering is begun one to two weeks after complete remission is attained. Most steroid-responsive patients will respond by 16 weeks though one study has reported remissions occurring as late as 21 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ]. In some patients, remission may be observed during the period of tapering when a \"fixed\" duration regimen of steroid administration is used for induction of a remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is gradually reduced by 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every three to four days and, once the dose reaches 20 to 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    the patient is gradually switched to an alternate day regimen and then tapered further over two to three months. One tapering regimen at this time is to decrease the alternate day dose by 5 mg every one to two weeks until the dose is 20 to 30 mg alternating with 10 mg. The alternate day dose is then reduced by 2.5 mg every one to two weeks until the prednisone dose on the alternate day has fallen to zero. At this point, the remaining drug is tapered in the same manner. The rate of tapering will be more rapid if side effects are limiting.",
"   </p>",
"   <p>",
"    Slow tapering is performed both to sustain the remission and to avoid adrenal suppression. Avoidance of adrenal suppression may be important for the renal disease, since a study in children found that moderate to severe post-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    adrenal suppression was associated with an increased risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shorter tapering regimens, in which steroids are tapered rapidly after remission is induced, are associated with an increased risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ], suggesting a \"rebound effect\". (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=see_link&amp;anchor=H16#H16\">",
"     \"Glucocorticoid withdrawal\", section on 'Recommended tapering regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who have not attained complete remission, the usual maximum duration of daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is 16 weeks, and patients who do not respond by this time are often considered glucocorticoid-resistant. Prednisone therapy is gradually tapered to lower doses in such patients and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is often started along prednisone 0.15-0.20",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    As mentioned above, partial responses are not characteristic of MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ] and, when seen, one should suspect a misdiagnosis, most often FSGS, that was missed by sampling error or an error in interpretation of the original renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Glucocorticoid-resistant MCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The variability in glucocorticoid regimens is illustrated by the following regimen recommended by some experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy is begun with daily oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 80",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Daily therapy is usually given as a single dose upon awakening in an attempt to minimize adrenal suppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At six to eight weeks (the latter more often used in patients over age 40 who are not in remission), the patient is abruptly switched to alternate-day therapy (1.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum 120 mg on the alternate days) for four weeks. Most patients tolerate this conversion to alternate-day therapy if daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      was given as a single dose upon awakening (usually between seven and nine AM) in an attempt to minimize adrenal suppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The alternate-day dose is then reduced by 0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks for a total course of 26 to 28 weeks.",
"     </li>",
"     <li>",
"      Because of a greater risk of glucocorticoid toxicity, patients over age 65 are begun at the same initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose (1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 80",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which is reduced to 0.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day after four weeks. At six weeks, the patient is switched to alternate-day therapy (1.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum 120 mg on the alternate days). The alternate dose is reduced by 0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two to four weeks for a total course of 16 to 24 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians prefer alternate-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    from the beginning to minimize the toxicity of long-term daily prednisone, at an initial dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day (to a maximum dose of 120 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. The time of remission may be longer with alternate day therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy in MCD, particularly if given daily, is often associated with significant toxicity. As a result, prophylactic measures should be undertaken as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone, or cyclosporine in combination with pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , have been used as initial therapy in adults with MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. However the use of these agents, especially cyclophosphamide, as a first-line therapy for patients with MCD and no associated co-morbidities is not warranted. These agents are more commonly used for frequently relapsing or glucocorticoid-dependent disease as described below.",
"   </p>",
"   <p>",
"    We occasionally use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone or in combination with low-dose (10 to 15 0.15-0.20",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for initial therapy in patients with relative contraindications to high-dose prednisone therapy, such as morbid obesity, uncontrolled diabetes, severe osteoporosis, psychiatric disturbance, or bleeding gastrointestinal ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    below.) We recommend not using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as a first-line treatment of MCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 to 75 percent of glucocorticoid-responsive adults will have a relapse, and frequent relapses occur in 10 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14,16,18\">",
"     14,16,18",
"    </a>",
"    ]. This section is limited to patients who relapse after complete remission and are no longer on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Patients who relapse while still on prednisone are considered glucocorticoid-dependent. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Frequently relapsing or glucocorticoid-dependent MCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who relapse off glucocorticoid therapy require reinstitution of therapy, and early detection is beneficial. We ask patients to test their urine with a dipstick for protein every one to two weeks initially. A positive test should be repeated the next day and, if still positive, the clinician should be contacted.",
"   </p>",
"   <p>",
"    There are no randomized trials to guide the optimal therapy of relapse. However, in patients who were able to taper off",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    after achieving complete remission, a repeat course of prednisone often results in a prompt clinical remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some nephrologists repeat the initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    regimen, whereas others (including the author) prefer a shorter course for a first relapse to minimize overall glucocorticoid exposure, particularly if the relapse has occurred after a relatively long period off prednisone, or when it is caused by an intercurrent benign viral or allergic event. In such patients, we administer oral prednisone at a daily dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose of 60 to 80 mg per day) for a minimum of four weeks; if remission is attained, the dose is then tapered in 5 mg increments every three to five days to discontinuation within one to two months.",
"   </p>",
"   <p>",
"    Subsequent relapses, if not frequent (eg, less than three per year), can also be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    if significant side effects have not developed. A longer course of prednisone (as administered for initial therapy), can be used in patients who relapse during the taper of a short course of steroids or within four months of completing the short course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FREQUENTLY RELAPSING OR GLUCOCORTICOID-DEPENDENT MCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of approaches in patients who have frequent relapses (often defined as three or more relapses per year) or who are steroid-dependent (which refers to relapse while on therapy or requirement for continuation of steroids to maintain remission) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Response to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Continuous low-dose (0.15-0.20",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may sustain a remission in glucocorticoid-responsive but frequently relapsing MCD. Other agents have also been used to treat frequent relapses, glucocorticoid-dependence, or glucocorticoid toxicity. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alkylating agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or, now rarely used because of greater toxicity,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antimetabolites (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"     </li>",
"     <li>",
"      Levamisole",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For frequent relapsing disease, these drugs are typically given after a remission has been induced with glucocorticoids. The decision to use an alternative approach depends in part upon the individual patient's tolerance of prolonged glucocorticoid use. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment of relapse'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In rare cases, consideration may be given to providing no further immunosuppressive therapy since many will eventually enter a spontaneous remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2\">",
"     2",
"    </a>",
"    ]. Such an approach may be used in frail elderly patients, diabetic patients, patients who have received multiple courses of immunosuppressive drugs, and patients whose nephrotic syndrome can be controlled with the nonimmunosuppressive therapies described above.",
"   </p>",
"   <p>",
"    In such cases, therapy should focus on the symptomatic treatment of nephrotic syndrome described above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Nonimmunosuppressive therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Low-dose alternate-day prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In glucocorticoid-sensitive patients who have frequent relapses, continuous low-dose alternate-day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy for 6 to 12 months or longer is often used to sustain the remission if steroid toxicity is minimal or tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In such patients, remission is first induced as described in the previous section.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is tapered to approximately 15 mg every other day or the lowest daily dose that sustains a remission. This dose is maintained for approximately 6 to 12 months, which is then tapered slowly to discontinuation over several months.",
"   </p>",
"   <p>",
"    A commonly asked question is &ldquo;What is the maximum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose that we would use to maintain remission in frequent relapsing or glucocorticoid-dependent MCD?&rdquo;. In our experience, patients who relapse while taking the equivalent of 0.2 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of prednisone per day often develop unacceptable complications if higher dose long-term prednisone is given to maintain remission. Such patients may be better treated with a four-month course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , given for a long period of time (one to two years) with the minimum dosage entertaining remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective observational reports suggest that approximately 75 percent of adults with frequently relapsing or steroid-dependent MCD remit following therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    at a regimen of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 8 to 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,16-18,21,29,43\">",
"     12,16-18,21,29,43",
"    </a>",
"    ]. Remission is usually induced or maintained with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    before initiating cyclophosphamide. Dosage of cyclophosphamide must often be reduced according to leukocyte counts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link&amp;anchor=H25#H25\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Blood counts and differential'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 14 patients, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for eight weeks) resulted in complete, relapse-free remission in four of five frequent relapsers and four of nine glucocorticoid-dependent patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"       16",
"      </a>",
"      ]. The remaining five glucocorticoid-dependent patients were able to be weaned off glucocorticoids, but had subsequent relapses. At final follow-up, 11 were in complete remission.",
"     </li>",
"     <li>",
"      In a prospective trial of 66 children and adults, 11 adults with frequently relapsing or steroid-dependent MCD were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for eight weeks) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for nine months, then tapered off by month 12) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/43\">",
"       43",
"      </a>",
"      ]. All of the adults achieved remission; three patients in each group eventually relapsed, occurring in the first year following therapy in with cyclophosphamide, and earlier after discontinuation of cyclosporine. Among children, the rate of stable disease at two years was significantly higher with cyclophosphamide (68 versus 20 percent). There were too few adults for a meaningful comparison although, as described in the next section, other studies have also found a high rate of relapse following cessation of cyclosporine.",
"     </li>",
"     <li>",
"      In three separate reports of adults with frequent relapses treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , remission occurred in 90 to 95 percent of patients, although some required therapy for longer than 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,17,18\">",
"       12,17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We administer oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    at a dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 12 weeks based upon published observations in adults and children and the author's experience that an eight-week course is less effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,16,44\">",
"     12,16,44",
"    </a>",
"    ]. Patients who are steroid-dependent have a higher relapse rate than those with frequent relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Among frequent relapsers, we first induce a remission with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and then switch to cyclophosphamide to sustain the remission.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is often given with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . However, it has never been proven that glucocorticoids improve the long-term outcome, and cyclophosphamide alone is highly effective in frequent relapsers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , prolonged therapy (&gt;12 weeks) and repeated courses should be avoided. In addition, some patients (including children) have mild (and often transient) relapses characterized by nonnephrotic proteinuria and no edema or hypoalbuminemia; in this setting, further treatment can be withheld although the patient should be monitored for progressive disease since persistent nonnephrotic proteinuria is more characteristic of FSGS (missed by sampling error on renal biopsy) than MCD. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Side effects of immunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their immunosuppressive properties calcineurin inhibitors have a direct anti-proteinuric effect on the podocyte [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a possible alternative in patients who continue to relapse after an initial course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , who are steroid-dependent, or in whom avoidance of the toxicities of cyclophosphamide (eg, gonadal toxicity) is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/1,41,45\">",
"     1,41,45",
"    </a>",
"    ]. Although experience is more limited,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has also been used, with no apparent benefit over cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Cyclosporine and tacrolimus have different side effect profiles, which may influence the choice of either agent as a treatment modality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If treatment with a calcineurin inhibitor is indicated following a course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , the treatment should be delayed until leukocyte counts have recovered in order to prevent opportunistic infections. We generally do not restart immunosuppressive therapy until at least two weeks after recovery of normal leukocyte counts, although this approach is not based on published data.",
"   </p>",
"   <p>",
"    Numerous observational studies and a small randomized trial suggest that approximately 70 and 90 percent of glucocorticoid-dependent or frequently relapsing patients, respectively, will undergo complete or partial remission when treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    at a dose of 4 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses (non-microemulsion preparation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/41,43,50-52\">",
"     41,43,50-52",
"    </a>",
"    ]. Neoral is considered to be more reliable than other preparations because of better bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/45\">",
"     45",
"    </a>",
"    ]. The recommended dosage of the microemulsion preparation (Neoral) is approximately 3",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    The response to cyclosporine is lower in glucocorticoid-resistant cases, being approximately 50 percent. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Glucocorticoid-resistant MCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following reports illustrate these observations in frequently relapsing MCD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the randomized trial, 11 adults with frequently relapsing disease were assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/43\">",
"       43",
"      </a>",
"      ]. Each of the six cyclosporine-treated patients remitted, but three patients relapsed following discontinuation of the drug.",
"     </li>",
"     <li>",
"      In two series of seven and eight patients with relapsing MCD, all but one entered remission following therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      at a dose of approximately 2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. However, five of eight patients relapsed during the cyclosporine taper or within a few months of discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Favorable results have also been reported for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy in patients with glucocorticoid-dependent MCD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two reports of patients with MCD who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (12 to 15",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      41 of 49 glucocorticoid-dependent patients (84 percent) entered remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. However, approximately two-thirds relapsed when cyclosporine was discontinued.",
"     </li>",
"     <li>",
"      An analysis of data from published studies that included 146 patients with glucocorticoid-dependent or glucocorticoid-resistant MCD found that 60 and 10 percent entered a complete and partial remission, respectively, following therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/41\">",
"       41",
"      </a>",
"      ]. As noted above, MCD is typically an all-or-none disease and partial remission lasting more than one to two weeks may reflect underlying focal segmental glomerulosclerosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As illustrated by these data, over 60 percent of frequently relapsing or glucocorticoid-dependent patients who respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    will relapse (usually within six months) after cyclosporine is discontinued if the duration of therapy is relatively short [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/41,43,55\">",
"     41,43,55",
"    </a>",
"    ]. A sustained remission is more likely if patients are maintained on cyclosporine for one year or longer, with therapy then slowly tapered to discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/41,50\">",
"     41,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is potentially nephrotoxic, it appears that prolonged therapy with lower doses of cyclosporine can maintain remission without nephrotoxicity. In one study, for example, patients who went into remission showed no signs of cyclosporine nephrotoxicity on repeat biopsy at a mean of 20 months as long as the daily dose of cyclosporine (nonmicroemulsion preparation) was below 5.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, we use the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and low-dose (about 0.15",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in patients who continue to relapse after an initial course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , who are glucocorticoid-dependent, or who wish to avoid the toxicities of cyclophosphamide, especially infertility in males. We use the following regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (the non-microemulsion preparation) is initiated at a dose of approximately 4 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (given in two divided doses). The more bioavailable microemulsion formulation (eg, Neoral) may require lower doses (eg, 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). We monitor cyclosporine levels periodically to ascertain compliance, absorption and avoid higher, more nephrotoxic levels (eg, between approximately 100 and 200",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal duration of therapy in responders is not known, but prolonged therapy is given to minimize the risk of relapse. We treat with the initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for approximately 18 months to minimize the rate of relapse, then taper to the smallest dose that maintains a remission (preferably 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of the non-microemulsion preparation and less than 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of the microemulsion preparation).",
"   </p>",
"   <p>",
"    An alternate approach is, once remission is established, to gradually taper to 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of the non-microemulsion preparation. This dose is maintained for 18 to 24 months.",
"   </p>",
"   <p>",
"    Patients who fail to attain remission after six months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy are unlikely to respond later. As a result, cyclosporine should be withdrawn and other approaches are considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      is given concurrently at a daily dose of 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 15",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      After approximately six months, we taper prednisone slowly to 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or 15 mg on alternate days), and maintain this dose for the duration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy. Although efficacy of prednisone therapy in patients treated with cyclosporine has not been proven, there is a clinical impression that remissions are more prolonged with combined therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient remains in remission for a minimum of two years, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    are gradually withdrawn.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    may be used instead of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , but so far no definite advantage of tacrolimus over cyclosporine has clearly been documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Levamisole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levamisole, which is an immunostimulant, has been tried in glucocorticoid-dependent children with the nephrotic syndrome. There are limited data regarding its use in adults with MCD. In a report from Hong Kong, three patients with MCD were treated with levamisole, which induced complete remission in two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Levamisole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in the treatment of MCD. There is some evidence of efficacy with prolonged (four years) azathioprine therapy in glucocorticoid-resistant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12\">",
"     12",
"    </a>",
"    ]. This observation suggests that azathioprine may also be effective in frequently relapsing or glucocorticoid-dependent disease. Azathioprine may be as effective as and less costly than MMF for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) has been shown to have some efficacy for the treatment of nephrotic FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/56\">",
"     56",
"    </a>",
"    ], and it is not unreasonable to postulate that it may be effective for MCD. Uncontrolled studies of MMF therapy in MCD suggest some benefit in patients with frequently relapsing or glucocorticoid-dependent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/21,57-59\">",
"     21,57-59",
"    </a>",
"    ]. In a retrospective study of seven adults who were glucocorticoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    dependent, MMF (750 to 1000 mg twice daily) was administered for 6 to 26 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/57\">",
"     57",
"    </a>",
"    ]. Proteinuria decreased significantly (mean urine protein to creatinine ratio decreased from 4.1 to 1.3) following therapy with MMF. One patient was resistant to MMF, four had a sustained complete remission allowing withdrawal of corticosteroids, and two relapsed following initial remission. In another report, one patient had no response to MMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials are required, but there may be a role for MMF in inducing or maintaining remission in adults with MCD who have failed therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or who have contraindications to glucocorticoids or other immunosuppressive agents. However, such use of MMF should currently be considered experimental. Moreover, MMF has not been shown to be superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in other conditions that require immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    (RTX) is a chimeric monoclonal antibody that recognizes the CD-20 subset of B lymphocytes. RTX has been used for the treatment of various glomerulopathies, including MCD, FSGS and recurrent FSGS following kidney transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. Most case reports were of children with MCD although a few small case series also included adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/66\">",
"     66",
"    </a>",
"    ]. The data pertaining to children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most case series report favorable results and minimal side effects,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    toxicity may be underestimated since it is likely that treatment failures are less frequently published than successes. As an example, in one pediatric collaborative study of 70 patients, 27 percent developed side effects, with three patients having more than one adverse reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/65\">",
"     65",
"    </a>",
"    ]. The most frequent side effects included fever, abdominal pain, diarrhea, vomiting, skin rash, bronchospasm, tachycardia and hypertension. Severe infections occurred in three patients and a number of severe delayed adverse reactions may have be due to rituximab, including cardiomyopathy, extensive rash of the lower extremities, hair thinning, pancolitis and rapid decline in glomerular filtration rate.",
"   </p>",
"   <p>",
"    We believe that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    should be considered an experimental treatment that is only considered when other options for therapy have failed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Approach to relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;A repeat course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is the treatment of choice for infrequent relapses of glucocorticoid-responsive MCD. The following is a summary of our approach in patients with frequently relapsing or glucocorticoid-dependent disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (eg, 15 mg on alternate days) is the preferred therapy for maintaining a prednisone-induced remission in patients with frequently relapsing disease who do not have significant glucocorticoid-related toxicity.",
"     </li>",
"     <li>",
"      The higher likelihood of a sustained remission makes a course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , the preferred therapy in most patients with frequently relapsing MCD who cannot tolerate continued glucocorticoid therapy. However, the hazards of cytotoxic therapy, especially that of male infertility, must be clearly explained to the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      his guardians for ethical and legal reasons before beginning this treatment. Such therapy is given after glucocorticoid-induced remission. Once cyclophosphamide is started,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is tapered and then discontinued as described above. Slow tapering to avoid adrenal suppression may be important for the renal disease, since a study in children found that moderate to severe post-prednisone adrenal suppression was associated with an increased risk of relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If relapse recurs following therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      is safer than repeated courses of cyclophosphamide.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      may be somewhat more effective, and less toxic, in glucocorticoid-dependent disease, and can also be used in patients who refuse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID-RESISTANT MCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional adults (approximately 5 to 10 percent) with MCD appear to be glucocorticoid-resistant. This is most often due to one of the following problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate initial glucocorticoid therapy due to treatment for less than 16 weeks (",
"      <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/22\">",
"       22",
"      </a>",
"      ]. A longer course of daily therapy induces remission in some of these cases. In children who do not respond by four weeks, a failure to respond to a trial of pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      is considered indicative of glucocorticoid resistance. Some nephrologists apply this approach to define glucocorticoid resistance (eg, methylprednisolone 0.5 to 1 g methylprednisolone every other day for three doses) in adults who do not have some response to oral glucocorticoids by 8 to 12 weeks.",
"     </li>",
"     <li>",
"      An incorrect diagnosis, most often FSGS that is missed by sampling error, particularly if the renal biopsy comprises few glomeruli and only superficial cortical tufts. As mentioned previously, remissions of MCD are typically abrupt, with the patient being free of proteinuria within one to two weeks from the time of initial response. Partial responses are not characteristic of MCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/13\">",
"       13",
"      </a>",
"      ] and, when seen, one should suspect a possible",
"      <strong>",
"       misdiagnosis",
"      </strong>",
"      , most often focal segmental glomerulosclerosis (FSGS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The first step is to review the renal biopsy, since segmental sclerosis in one glomerulus is sufficient to establish the diagnosis of FSGS. Some would perform a repeat renal biopsy if reevaluation of additional glomeruli on the original biopsy specimen is not revealing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/67\">",
"       67",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoid-resistance may also be seen in one of the variants of idiopathic nephrotic syndrome other than FSGS, such as idiopathic mesangial proliferation, IgM nephropathy, or C1q nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=see_link\">",
"       \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Repeat renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on repeat renal biopsy in MCD are limited. In a review of 25 children with MCD who underwent repeat biopsy, most often prior to a change in therapy, four had MCD and 21 had FSGS or IgM nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/67\">",
"     67",
"    </a>",
"    ]. The distribution was different in a series of 35 adults with MCD on initial biopsy: repeat biopsy showed MCD in 22 and FSGS in 13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the value of repeat biopsy in glucocorticoid-resistant MCD is unclear. Histologic examination will show either FSGS or MCD. However, if MCD is again seen, one cannot exclude underlying FSGS that was missed by sampling error. Furthermore, the findings on repeat biopsy do not affect therapy, since the treatment of choice is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for both glucocorticoid-resistant MCD and glucocorticoid-resistant FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ]. On the other hand, some (including the author) consider the finding of FSGS on repeat biopsy to be valuable in glucocorticoid-resistant patients, since it identifies a patient with a worse long-term prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Steroid-dependent and steroid-resistant FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy for glucocorticoid-resistant MCD is not well defined. Limited data indicate that some of these patients respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ; late relapses can occur and are sometimes glucocorticoid-responsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2,19,22\">",
"     2,19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has documented efficacy in glucocorticoid-resistant MCD although long-term results are less well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/21,41,53,68,69\">",
"     21,41,53,68,69",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial evaluated the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      in 13 adults and children with glucocorticoid-resistant MCD compared with supportive care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/18\">",
"       18",
"      </a>",
"      ]. The cyclosporine dose was 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for six months, which was then tapered by 25 percent every two months until discontinuation. Complete or partial remission was induced in five of eight treated adults without significant nephrotoxicity or other side effects. As mentioned above, MCD is typically an all-or-none disease and partial remission lasting more than one to two weeks may reflect underlying focal segmental glomerulosclerosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Positive responses occurred within",
"      <strong>",
"       two months",
"      </strong>",
"      after the onset of therapy, while lack of antiproteinuric effect at three months was generally indicative of resistance to cyclosporine. Despite the initial benefit, relapses were common after cessation of therapy and mean urinary protein excretion at the end of the study was not different between treated and control groups.",
"     </li>",
"     <li>",
"      In a report from France that combined two prospective uncontrolled trials, 21 adults with glucocorticoid-resistant MCD were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (10 to 15",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/53\">",
"       53",
"      </a>",
"      ]. Fourteen patients were in complete or partial remission at six months, but many had recurrence of proteinuria upon cyclosporine taper. Responses were more likely among those concurrently receiving prednisone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be effective in glucocorticoid-resistant MCD. An uncontrolled study in 13 glucocorticoid-resistant adults reported remission in all patients with prolonged therapy (four years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with glucocorticoid-resistant MCD usually develop progressive kidney disease, by which time focal segmental glomerulosclerosis (FSGS) is present if repeat biopsy is performed. In studies in patients with glucocorticoid-resistant FSGS,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    often induces a complete or partial remission of proteinuria (70 percent in a randomized trial compared with 4 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/70\">",
"     70",
"    </a>",
"    ]. Partial remissions in FSGS are associated with a better long-term prognosis than seen in patients with no response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/23,70\">",
"     23,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Response to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Steroid-dependent and steroid-resistant FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, we treat patients with glucocorticoid-resistant MCD with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in combination with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , using the same approach as for frequently-relapsing or glucocorticoid-dependent disease. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach to glucocorticoid-resistant patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is not well defined. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    were effective in some reports of glucocorticoid-resistant patients, these patients were not also cyclosporine-resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12,13,29,60\">",
"     12,13,29,60",
"    </a>",
"    ]. Our approach is not to attempt further immunosuppressive therapy and to use nonimmunosuppressive therapies (eg, diuretics, angiotensin inhibition, statins). (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Persistent nephrotic syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Secondary glucocorticoid resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are initially frequent relapsers or steroid-dependent can develop secondary glucocorticoid-resistance. Renal biopsy at this time may show FSGS, which may either have been present from the beginning or may have evolved from MCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/71\">",
"     71",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is often effective in this setting, but some patients develop progressive renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS OF IMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive agents used to treat MCD are associated with significant side effects. These toxicities are described in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"       \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term complications of cytotoxic therapies may be less common in MCD, since relatively short courses are used. However, the toxicity of these agents must be considered in treating patients with MCD, particularly since progressive renal failure is rare in the absence of progression to focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PERSISTENT NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rare patients who have persistent nephrotic syndrome despite adequate courses of immunosuppressive therapy should be treated with other therapies, such as angiotensin converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs] to reduce proteinuria, diuretics to control edema, statin therapy for hyperlipidemia, and, if necessary, therapy for thromboembolic complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link&amp;anchor=H12#H12\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated minimal change disease is associated with potentially fatal complications, including sepsis and thrombosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      leads to complete remission of proteinuria within four months in over 90 percent of adults with MCD, and is the treatment of choice (",
"      <a class=\"graphic graphic_figure graphicRef58623 \" href=\"mobipreview.htm?41/47/42751\">",
"       figure 1",
"      </a>",
"      ). Approximately 50 to 65 percent of adults will have a relapse, and repeated relapses occur in 10 to 25 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remissions are typically abrupt, with the patient being free of proteinuria within one to two weeks from the time of initial response. Partial responses are not characteristic of MCD and, when seen, one should suspect a",
"      <strong>",
"       misdiagnosis",
"      </strong>",
"      , most often focal segmental glomerulosclerosis (FSGS) that was missed by sampling error.",
"     </li>",
"     <li>",
"      Since minimal change disease (MCD) accounts for only 10 to 25 percent of cases of nephrotic syndrome in adults, therapy is begun after a renal biopsy suggests a diagnosis of MCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"       \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the potentially fatal complications associated with untreated nephrotic syndrome and the high response rate to an adequate course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , we recommend initial therapy with prednisone in patients with MCD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We use oral prednisone at an initial daily dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of body weight (maximum dose 60 to 80 mg per day), which is continued for 12 to 16 weeks and is subsequently progressively tapered to discontinuation over the following six months. Shorter treatment courses are often complicated with relapses. Exceptions to this approach are discussed above. (See",
"      <a class=\"local\" href=\"#H445388995\">",
"       'Glucocorticoid therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Other immunosuppressive agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the therapy of infrequent relapses in steroid-sensitive patients who do not have significant steroid-related side effects, we suggest repeating an abbreviated course of high dose oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment of relapse'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with frequent relapses but no significant steroid-related side effects, we suggest a prolonged course of low-dose oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (approximately 15 mg on alternate days) to maintain a steroid-induced remission (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Low-dose alternate-day prednisone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent relapses in whom avoidance of continued steroid exposure is desired, we suggest a course of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , given the lower rate of relapse and shorter duration of therapy with cyclophosphamide (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We treat with an initial dosage of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 12 weeks, usually beginning after remission has been induced or maintained with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . Dosage must often be reduced according to leukocyte counts. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cyclophosphamide'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link&amp;anchor=H25#H25\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Blood counts and differential'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who continue to relapse after an initial course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , who are steroid-resistant or steroid-dependent, or in whom avoidance of the toxicities of cyclophosphamide is important (eg, gonadal toxicity), we suggest therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing, monitoring and duration of therapy are discussed above. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Glucocorticoid-resistant MCD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/1\">",
"      Bargman JM. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999; 70:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/2\">",
"      Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970; 3:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/3\">",
"      Coggins CH. Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 1986; 97:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/4\">",
"      Imbasciati E, Gusmano R, Edefonti A, et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J (Clin Res Ed) 1985; 291:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/5\">",
"      Yeung CK, Wong KL, Ng WL. Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome. Aust N Z J Med 1983; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/6\">",
"      The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/7\">",
"      White RH, Glasgow EF, Mills RJ. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970; 1:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/8\">",
"      Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/9\">",
"      Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/10\">",
"      Gesualdo L, Di Palma AM, Morrone LF, et al. The Italian experience of the national registry of renal biopsies. Kidney Int 2004; 66:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/11\">",
"      Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/12\">",
"      Nolasco F, Cameron JS, Heywood EF, et al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986; 29:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/13\">",
"      Fujimoto S, Yamamoto Y, Hisanaga S, et al. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991; 17:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/14\">",
"      Nakayama M, Katafuchi R, Yanase T, et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/15\">",
"      Korbet SM, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988; 8:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/16\">",
"      Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 1996; 11:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/17\">",
"      Arneil GC, Lam CN. Long-term assessment of steroid therapy in childhood nephrosis. Lancet 1966; 2:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/18\">",
"      Tse KC, Lam MF, Yip PS, et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003; 18:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/19\">",
"      Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.",
"     </a>",
"    </li>",
"    <li>",
"     Meyrier, A. Management of idiopathic nephrotic syndrome in adults: Minimal change disease and focal segmental glomerulosclerosis. In: Evidence-Based Nephrology, Molony, DA, Craig, JC (Eds), Wiley-Blackwell, Oxford 2009, p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/21\">",
"      Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/22\">",
"      Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 2000; 84:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/23\">",
"      Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/24\">",
"      Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/25\">",
"      Pru C, Kjellstrand CM, Cohn RA, Vernier RL. Late recurrence of minimal lesion nephrotic syndrome. Ann Intern Med 1984; 100:69.",
"     </a>",
"    </li>",
"    <li>",
"     Galle, J. Reduction of proteinuria with angiotensin receptor blockers. Nature Clin Pract Cardiovascular Medicine 2008; 5: (Suppl. 1) S36.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/27\">",
"      Mathieson PW. Proteinuria and immunity--an overstated relationship? N Engl J Med 2008; 359:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/28\">",
"      Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int 2009; 76:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/29\">",
"      Huang JJ, Hsu SC, Chen FF, et al. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol 2001; 21:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/30\">",
"      Nair RB, Date A, Kirubakaran MG, Shastry JC. Minimal-change nephrotic syndrome in adults treated with alternate-day steroids. Nephron 1987; 47:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/31\">",
"      Wang F, Looi LM, Chua CT. Minimal change glomerular disease in Malaysian adults and use of alternate day steroid therapy. Q J Med 1982; 51:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/32\">",
"      Vande Walle JG, Donckerwolcke RA, van Isselt JW, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/33\">",
"      Koomans HA, Boer WH, Dorhout Mees EJ. Renal function during recovery from minimal lesions nephrotic syndrome. Nephron 1987; 47:173.",
"     </a>",
"    </li>",
"    <li>",
"     Salant, D, Dember, LM. Minimal change disease. In: Therapy in Nephrology and Hypertension, 2d ed, Brady, HR, Wilcox, CS (Eds), Saunders, Philadelphia, 2003.",
"    </li>",
"    <li>",
"     Meyrier, A, Niaudet, P. Minimal change and focal-segmental glomerular sclerosis. In: Oxford Textbook of Clinical Nephrology, 3rd ed, Davison, AM, Cameron, JS, Grunfeld, JP, Ponticelli, C, Ritz, E, Winearls, CG, van Ypersele, C, (Eds), Oxford University Press, Oxford 2005. p. 467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/36\">",
"      Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA 1999; 282:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/37\">",
"      Leisti S, Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression. J Pediatr 1983; 103:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/38\">",
"      Al-Khader AA, Lien JW, Aber GM. Cyclophosphamide alone in the treatment of adult patients with minimal change glomerulonephritis. Clin Nephrol 1979; 11:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/39\">",
"      Matsumoto H, Nakao T, Okada T, et al. Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin Nephrol 2001; 55:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/40\">",
"      Matsumoto H, Nakao T, Okada T, et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern Med 2004; 43:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/41\">",
"      Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003; 18 Suppl 6:vi79.",
"     </a>",
"    </li>",
"    <li>",
"     Meyrier, A. Management of idiopathic nephrotic syndrome in adults: Minimal change disease and focal segmental glomerulosclerosis. In: Evidence-Based Nephrology, Molony, DA, Craig, JC (Eds), Wiley-Blackwell, Oxford 2009. p 149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/43\">",
"      Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993; 8:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/44\">",
"      Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Arch Dis Child 1987; 62:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/45\">",
"      Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int 2007; 72:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/46\">",
"      Westhoff TH, Schmidt S, Zidek W, et al. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol 2006; 65:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/47\">",
"      Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/48\">",
"      Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 2008; 23:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/49\">",
"      Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/50\">",
"      Meyrier A, No&euml;l LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Soci&eacute;t&eacute; de N&eacute;phrologie. Kidney Int 1994; 45:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/51\">",
"      Goumenos DS, Kalliakmani P, Tsakas S, et al. Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels. Med Chem 2006; 2:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/52\">",
"      Koike M, Honda K, Tsukada M, et al. [Low-dose cyclosporin therapy combined with prednisolone for relapsing minimal change nephrotic syndrome in adults]. Nihon Jinzo Gakkai Shi 2002; 44:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/53\">",
"      Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991; 35 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/54\">",
"      Lee HY, Kim HS, Kang CM, et al. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Clin Nephrol 1995; 43:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/55\">",
"      Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis 1991; 18:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/56\">",
"      Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 2009; 5:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/57\">",
"      Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/58\">",
"      Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/59\">",
"      Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/60\">",
"      Cade R, Mars D, Privette M, et al. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 1986; 146:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/61\">",
"      Remuzzi G, Cravedi P, Costantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/62\">",
"      Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/63\">",
"      Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/64\">",
"      Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2012; 27:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/65\">",
"      Prytua A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/66\">",
"      Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/67\">",
"      Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994; 125:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/68\">",
"      Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/69\">",
"      Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/70\">",
"      Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/9/31898/abstract/71\">",
"      Meyrier A. Treatment of idiopathic nephrotic syndrome with cyclosporine A. J Nephrol 1997; 10:14.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3045 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31898=[""].join("\n");
var outline_f31_9_31898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KIDNEY FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonimmunosuppressive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445388988\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H445388995\">",
"      - Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Time course and patient age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FREQUENTLY RELAPSING OR GLUCOCORTICOID-DEPENDENT MCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Low-dose alternate-day prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Levamisole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Approach to relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GLUCOCORTICOID-RESISTANT MCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Repeat renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Secondary glucocorticoid resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SIDE EFFECTS OF IMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PERSISTENT NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3045|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/47/42751\" title=\"figure 1\">",
"      Response to steroids in MCD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=related_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_9_31899="Exit site scoring system";
var content_f31_9_31899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peritoneal catheter exit-site scoring system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" style=\"width: 628px; height: 246px;\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        0 points",
"       </td>",
"       <td class=\"subtitle1\">",
"        1 point",
"       </td>",
"       <td class=\"subtitle1\">",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swelling",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Exit only; &lt;0.5 cm",
"       </td>",
"       <td>",
"        &gt;0.5 and/or tunnel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crust",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &lt;0.5 cm",
"       </td>",
"       <td>",
"        &gt;0.5 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Redness",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &lt;0.5 cm",
"       </td>",
"       <td>",
"        &gt;0.5 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Slight",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drainage",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Serous",
"       </td>",
"       <td>",
"        Purulent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Infection should be assumed with exit-site score of 4 or greater. Purulent drainage, even if alone, is sufficient to indicate infection. A score of less than 4 may not represent infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Piraino, B, Bailie, GR, Bernardini, J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107. Copyright &copy; 2005 Peritoneal Dialysis International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31899=[""].join("\n");
var outline_f31_9_31899=null;
var title_f31_9_31900="Adolescent suicide Oregon";
var content_f31_9_31900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Number and rate* of fatal and nonfatal suicide attempts among persons aged 10-17 years, by age group and sex - Oregon, 1988-1993",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Attempt/age group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Male",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Female",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rate",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rate",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Nonfatal&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-14 years",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        26.6",
"       </td>",
"       <td>",
"        1037",
"       </td>",
"       <td>",
"        174.0&nbsp;",
"       </td>",
"       <td>",
"        1204",
"       </td>",
"       <td>",
"        98.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-17 years",
"       </td>",
"       <td>",
"        556",
"       </td>",
"       <td>",
"        156.1",
"       </td>",
"       <td>",
"        2013",
"       </td>",
"       <td>",
"        594.4",
"       </td>",
"       <td>",
"        2569",
"       </td>",
"       <td>",
"        369.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total",
"       </td>",
"       <td>",
"        723",
"       </td>",
"       <td>",
"        73.4",
"       </td>",
"       <td>",
"        3050",
"       </td>",
"       <td>",
"        326.4",
"       </td>",
"       <td>",
"        3773",
"       </td>",
"       <td>",
"        196.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Fatal&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-14 years",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-17 years",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        20.2",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        13.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Per 100,000 population in specified group.",
"     <br>",
"      &bull; Source: Oregon Adolescent Suicide Attempt Data System.",
"      <br>",
"       &Delta; Source: Oregon death certificate data.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from MMWR Morb Mortal Wkly Rep 1995; 44:312.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31900=[""].join("\n");
var outline_f31_9_31900=null;
var title_f31_9_31901="Minor congenital malformations A";
var content_f31_9_31901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78729%7EPEDS%2F55104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78729%7EPEDS%2F55104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minor congenital malformations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Head and craniofacial structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Skull",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal hair whorls (absence, more than 2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frontal bossing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plagiocephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flat occiput",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metopic fontanel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Eyes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epicanthal folds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotelorism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertelorism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upslanting or downslanting palpebral fissures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short palpebral fissures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Synophrys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ear lobe: attached, creases, notches, or bifid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small ears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lop ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cup-shaped ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protruding ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ear tags",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preauricular sinuses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Nose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flat bridge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anteverted nostrils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Philtrum long, short, flat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mouth and jaw",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microstomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Macrostomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bifid uvula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple frenula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micrognathia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Webbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Redundant skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Branchial sinuses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minor congenital malformations, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extra nipples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sacral dimple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shawl scrotum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal tags",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minor hypospadias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Arms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cubitus valgus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dimples over major joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fifth finger clinodactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single transverse plamar crease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bridge crease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tapered fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nail hypoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistent finger pads (fetal pads)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Partial syndactyly between 2-3 toes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nail hypoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prominence of the heels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Overlapping digits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypo or hyperpigmented macules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemangioma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31901=[""].join("\n");
var outline_f31_9_31901=null;
var title_f31_9_31902="HCW HIV cases since 1985";
var content_f31_9_31902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Cases of healthcare workers exposed to HIV/AIDS since 1985",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 373px; background-image: url(data:image/gif;base64,R0lGODlhEAJ1AcQAAP///wAzmQAAAMDAwEBAQICAgAAZTAAMJgAmcvDw8BAQENDQ0ODg4DAwMGBgYKCgoCAgIFBQULCwsJCQkHBwcAAJHAAGEwADCQAcVgATOQAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAQAnUBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkF8DA5GVlpdcDBACIwsKAgIKC5ikpaZJBaCcIhECEhICEaeztLU5DAOgI7oAvLa/wMEpvry+wsfItcSrxiMEz9DQydPUhr6tr7Enk9zcq9Xg4XmpqgUAnqCiL9/i7e5vuNwMI5Mx7O/4+YH3+v3+d/z+CRzYJiDBgwjHGEzIsGGWhQ4jSnwCcaLFi0UqYtyYLF69Kho5ivwFS1XIJCdH/6o0RUAAhQIwraRcSdOSAwJaZtbc6UiCgm4yeQqdRU5V0KFIMQ2AyfRo0qeVFlC6ohOq1T4JGqQbBfKqV0UOFLyEAMHp17ODCJgDkMss2rd+HDSQMCBC2a5w8/ZBB+qBkAkEIkiAUVWv4TQMJhTgCoRCLK1TWxQ+TFmRLliyXEyuzJmL2qLNeHySKgCn5s6o2VB48CCa6R/kPmUu0a3b5tS4qzDgulsIrlQTTriGdju3cSgFTLcF8qCAAwENEqw7Tj0MAQgKnm0K0prABOnTq4vnYhLUWirFx6sf8oBCzvXwrUggMC/C+Snp4+vXEcGBiAf59RDgfgTSoJYIy6FX4P+CSlCgwAMDNNCAWwxWGAQDn4AyGF4WdhhEAooxpqCHJPoAWHP3STFgiSVOYN4DClDI4owyBAZTgvjRqKOBL8EUI4c7BtkCgGQJ4B+QQiaZgoOxgDeiklCSsFpvD0VppQgEvPQaVVda+Vx5K+oQZpfVJeAAdtHISOaOA/hV5ZpRohiTEJM4KRmcUII2ZicZKrDhnXgmSYCf3ATRUjZbrrBnoLhRkGhj0DnmJqCM7ggLUynykECfIiqKlke1hVrbPJXSoGcQm4AYinDDtYRWARYcIOustNYqqwWZluoCqJH5MNoCq5ogKo5XFWBAAMgmq+yyyBqQq65TAJjOpCwsipD/scxmq6yz0MLwWXlCJPBReF9hq6223HbrwmrdSYOkVeaey2y66qph7UHxyrvts/Uq9Oqx+i5Lb79n3EtQvgEHMDDBJ9j5ZrkAJ9wsvwyzpYADnb4LFcIBL1wxCQtsAt13XJ7Fsb4ef0zCAGGBcuSTXp0sb8oqk5BASwbPkLNAMp9Lc80StCzAXTAXG7HEP1ccsiqClQyxxMkmzXAuEJCMxc7/9IwuxQxT+Z7JRycsNcE4EhsF1v5one3Y/eYSjVZqJqX2vFyTDSba5MYcdsd1ty1ANy7GjdTcAvddLwP3IS74UITvW7MJ4oa6uFCNR224urmAGYRU3GQ8zL9QT/x4/wkLaFfaM4aa9OjnYIeu8OX9pkIE5y29XC3oobPNsOxFMAAKqZTq7bru6pZ+3emr8/Cc7SuLiveQrUYfDbVwOCq99J1WLvro9Nzt2+8oRP88CwVkgMD56Kev/vkZwE4GARisL3/6FfQKgPavcz9C5LUJUbs9VcAf8cpAAAS47gD2E6D79KeDXCgAeKehggLpUMADJnBvKFsgA5swvhVMcA4VDB0CS/DBDZIngBicmQatY0ARXnB4K2QUhE4owRT6LIZfCCHURkiCEnLvM8lTEQphSMEW7vCFucMhniKgADS5q2jIseHWimhBEkpxbUqE09LApTEn+BAOOpQYD0fwRf/utedrUyijG8KYsDGKQI2jS8xinCYFOLKBjQFz4/2uSDcTniNDAqDe2YaYRCq60IpENGEE5lKXH0HxCXZcAx71pcdIfuxAbOmgp2qYSDlMUl6V5GPh/OigsUyoi02wZBo+ea5QdpKBWdnK5FAhSseB0IhiRCLUBtgvqVyNkLvMomdw2UZdIk2YfhyCJlOgSjSwUluuLGQy0VjHWlrOkEdEpDSn+UtObjMOz8xWNIPpx6UAgAIRgKAQvUnOW1axh9bc3gYdEAFpzSZH7DwmNnOpzXZuUC2OgcUskdDMM4STWePUpyIXSQCz8WABrRDA5ZaJgoKa4aDLSqjYkLmmkhT/gAJE8wGGHjSu2+Vzo/ssZj8VasIHBGcCf/KBY2ASnLxFwaIEJGYejYlSPy6gAG2KaQ9a0oBNME8FFD1BGa93PUMxNXolwKiyNMo3P3p0AiEd6t8SEBoAiA+YLN3F/MaKAGsJgKzzu4dUk0XVDPpxkQ4AqrUkxVVHNi9USTVBGQXgugCYta9q1SkleVpVE36mAAC6kAKaGEibRvGVIuCr6/462agKFpSEdasJC5CdQd1TpIqx3ybTGM/8lUCyoaNsai37TjKWlpfdimUoPEcRsPaUBKiFmmp1y9pDwhOyDPQlHW/62kzlVmK7RW5vs/nbb+rvARHIyk8GeoS9AjYI/8dNWGBb+8bivtUBLoLAKR/pRe+e9rpAyG7Atutb1wJ3dGoJi0Nre9LC4ha9P1CvvtjLXPc6l3tygQABBIpKJli3sunFL5Yu28rMqtCnGpILdY1w4NUmGMHOYDA0HXzDZPZmAOocZH01e18M+0C/8uIvP5vrzw3KiaM7yOtKb7sLBQvIxmtFVlsfbEIXmWTCRagwby9s4Qxzd4/vfdwzGjABRwGZCEJWLpGHbOT2djfJNVNLPefrBBmzOKyRtTEPUHwuFav0yzTWX38mwNgnDyHK2sUujjUsTg5P0YRLiaUgoeBl/7Y4zCa+caBzHIAdd9iEP51HAYQqYtICl8zaSv9unElAaEPfeZ6m4aybhQDn9cp50HRGqJ2x6EdMcpmDtrVvjQM95jkfGafqkss8zrTpIHR6v58u8oJfbd4NZs48tQbCrVOcayrv2spI/i/36uKd4T72v5DOlqQ9TelQZ3TUfeTmm00y0VSTeNW6FnS4K43tUWqb06W5kWMh2WtwG1vc7yb3jFV9bh+kQi2iRaq3eVzicLca1LzGcr1xUIAG4KymtHEeD54KVTTTuxdijrGrkQ1rXb24KUOAxeq+GmO0yu8ewy5zsaVc5f5eWdkqwxkXYQOhVhyVdWKyccgjPfJJl3zFfgbz46TSn0k4GQgRhY7D9C3xQM9c2jWn9s3/z5zzNP/QPZkUglRoC/McRJtZIG83oP1d9HFbe6rltuU8XVIA7ATbBFdfVtYfHfGYA5ziWueebBtbYBmkXVlrh3bbrT5xkyf7z8EdwNAbzXejx/3uyZo2rqsdcJTXLAGtcM5nCY8DxCMr74C3vF+Tvvil73Te39afYyCw6D7v4t/hPjrWOU9sxsNd4Jfs0amZsCLNY17ntme9yF3v94pDKwL2KYBdzn5ew7Od1V2P99fZGvZr4pnbxO/3u1Wvdt3TnPc4PznguSeBCDQ7+u4mufZxv/fK9z37f9f56Mz5sMKn/vDlv0Husc/08Tt9dIFrv/mNr3fku93rjbd9O0co/yW1Tv83ffDnf+6nfAGofo9zKnVnDzKXgFx3gOLnVcunY80nTwy0FJgCfluHgMdXgQt4gfLmcKE3cHyGeiLYfyS4fwD4eo5XMeziGiAIcfyXefFnA/PneYMFevz2QzCxcvhkgTZnfw/Xgyd2fvWXfvengqiWfBdIfXhnfUhHf5+HgkH4XDYYgYQxgSP4bixoghlYaBtoWhsEgRcyJxFkhEqHhCmohPBGhg34hPrjAFAXBFoxE7UHhi4ohlJ4hBhYhw+3QY7BaRlCGGMoiFSYeFa4elj4g1p4aC5GHHbVA8BSEooYiG/ohEkoZtbDcNGQMXJ4gk1XiFMQiqL4DFTHOP+q8CB62ACZk28c54adB4dbiIP+Bj8epz71g3ZMmIWnmIJUwIu9iD6/yCKaIywKx4m36IlxKGamGH6COI3QmIvFWIZ6BBUeiCkwhnZ8uIid2IiXZwLWqIsMKIMCKAXn+BR60lU7gDrrVgNySI6bt1zoh450qI4OyI7amG9JMQEO4HMRUID0ZYutN4y5KIeDiGz6WI3/CISUeAXtmBRZgiCXSHny54c6yGrnWIoROYmXRpEh6RXPMRYZuYLOmJC4OJEheIEN6XcP2YnW6HtHUJFIMXd7dpAlyIgUKIYfGYySqJAuWQU4mRRSMXgqiZC7R5Qj+ZKCGJP5CJKESIxTcJT/QsFm82BwN1iPPwmTQfl2vRd32XhkUHGRAEBg5EUDXhmGYFmS1EiTcHmNRVmWDvkUaKmWRdiT4/iVURmWMTiWsPcEWMkTLhJXCjB5S8mXz2iP/ACY6SiYMwgFhbkTNyNLXrgOHEl+HjmXM/mMNUmWV+mZViFcXbmZTseQkLmPkrmOUVCZO/Fip5mDnLmLnkmV/GiHr0maAUmEBsiYLEmXT/mZwSmVTUicTXlsrdmPu2mWeEkATPZza6kzqPmJnWmWuLmcukmZvIkUWgYhphdZ4tiYftmJximMcQmac2mTRgCbNLFmbZaZmlGd0XidDpmd6MeeReCeK5FnWrGTXTae/8HpmOZ4m0KJWRI5nHYpk3DSh7SZmtJooGKZn6Lpj865Jg76fm75lxIamBQ6mE7An/AROQC0kskpnKRWfLaJnQfaYAmaolggourhY6EQYlUHgy3YkSt6ny26YS+abTHanUMhkK2oA6wxAC3RbSZ6fU4Jo+lZnKsJkVWJjaN5oYMDCkymlDtQF38zj2xJnwsZoSw6oU2on0QgoyOxACDlMgBpdaUxeMOyCqvYhdI3heX5jOc5lE96oqEJXHOaJj+ApiKhpoB0L5jBKsPBDMeYPvzQln/4lmPqoWV6eIuKPosiqBtBDqTHAN3HciyjDRHEkI6qo0DZoZH5oY8alTqAqf8YIZBtugNBBwFFiltQaZ6jWpulGqmnOqkbap6rKqQLwjklKqpgWpSqaaqsiaqkCpO/aqU8oYpPhE/E+qDWuaMyiZ+8mqq+mgOsOhEq92N4Ma0aqq14GqVyOaXGuoMGAqxWwgxidqsQap/X2qN19qPmVqeqyq3sShOc0z/h+q7FOpzHqqvJmq3Lmq840K0S8a1G8a+sBq/Vmqs8SqboiaJAuqdMOlT7uhIXx4bSCrDUWp/WOpX0Kmr2KnYYe4U+oLAWASpHIa45iquQOrGSWrEEGqgbSxMl0bAjArN22qvliqxSmpsRy6z66qxCYRcQcBPj9bEPG7BOWqtBS7BDq53/RYuwN8CyC5scdJGS9OWzPgm0UCq050q0IguIR3uXFvkSDdAKLwuy43qw5mmu6omuAquuM6C1EQFdGGIkb/u0IRum8kqyFKunFnuvKQuJK5uzO4ELJQO2fSm2J5qnCKqiu2qzd1qczaq2SSGbDutvEHu2MzuvhVu5TXqxUqu5acugcuObIga55Cm5GauchFuzhnuzi4u0PDEodGGQKgm7A5q5k0u3wdmn5Kq6Ccu4KiGdjwu3MRuvI3uc2Iq5squyGqu7O3EpGNezzvuzxzu8ZFu3Ziu4L2gDeusQaui0oAu1qIucs0u5Lmq5BUu93/u+m8u6SMErQiAB6hYewHui/7jrg6abuNUXiQN8uCibupN7v/kIFXI0qzbwa67gv90btvVrvbQrvSV7bSfrfPi6rcmLvTXBF3T3A47rIkGEdgr8vqFLvhJLurZ7wAG8cMo7EotEF0xEBADycijgroAbtzLLoVRbtlYrulhrvjUsBn8arZK0FrOHAwmAHTbKcf87uzMMvz4qv1WrrEEMwlmbxGFwVpVaVm9QSmXXtD4QMuqwDc1YxRh8xcTLp+spvPa7ug1cEHgbBrK1xj8wAJ8QV0rqxorbknc7uBpcuvF7uoi7whgcj2AMBgy5BqYpbK7LOoJcwIqcwO7byHE8u8Yrt3jKwMfpBpFsBgvAAPr7uf9i2MLpasgVu8mDjMX1KpJRC8uYfL2cuwalTEBDCK7c+8PPe7VzG77FO8fVG8uOLMJmsMtkACHd6LHrdMlVSMvtO7A0e7m3S8eNLMqvTMp5DAZtIgILgHDqu8rsu8i2PM0GnMgErM4ZTL+gjLxfrMxlwMxlkBwioJfRXMGRe8HI3MkY/MldHMp2PMp4rID1XB5eG6Dp7Iha3M/xDL5DLL5F7MJGG8K5bC/f7AXX0VkD9rfrG7itHL2vPL3ZfMy3TMP0TAb2TAbh/CbS7NCZ7MHtLNMCzM6MHMsCDb1oi9H4q8sb/QWe+8shDcQ8Pbq1i80yrM3IzM2G+wYtPQY0Co//DB3T5UjN6GzNMKzUOH3FTn3AUB3UXbBkTZbCtJfTKd3QVz3THIjW7vzOT23SS43Sb53MGZ0GUa3EwgeeIG3OIl3IJB3XGwx2HdzWan2PuXvXaJDXYQCf26HKMMnKgP3CST2/J+3Paf3VOB3WCF0G/lnC5RzZ56zJWl3ZW2ywAy3PSLzSCiHWpuDDRR3MRjzME13MdlvLjB0D53s1rr0FkAcK0dXXov3XuC2m12zZc43Zda3ZWSwHuf0Fz2FwpSHcUSnZxe3Kgo3IzU3I112+NbDbVNHbWoCW+UfUfm3Uwjy1x33a8JzaC1zQ3XzQ3j0GLIMgWfW6/By7ym3TcA3W/3Ld1Uyd2fD91N7c2WTwjqYH2+ct2xYtxOtNxFx81Ef83Y/8Bc/tBe0CqD8AGBB8eofdqKNN027N37Jssg9N0RGe3qpN4awtBhdOCAuwh6+qwh8OjMRdzca91cgN4HRN4sw9y84t3lmQvj2AOJsw46c14mtd00uOwCJe4/h4yDHM4/vd5GwxLFhukOC9A/2a5aEydC/OBe2iAGi8sl3Kxnil5IjN5Gvu5IZd2lLO1dvt5mjI5o1qK3heK49Z4UNAABWQ54B+AaIV5l/AvIF65ubYKgo+3Og92+qt4+x92RHNwjl+x8354AS9Bm7rP4gOKFbd5nBMzHJ82zgOzEht0P+XDulefM8mcd9cPiiRQsGmbsGTzsmi7snGXOVtDuXrPOcLatqr3szQEAEdPgOIwxQASuOffnsSTtuYbtvjO9ILfurxnerAnulmIC7SAWLUbash/uaVHuc7PudXDOfVzp21/d5nAFLSMXyQXd3fXudqvufpjuukntX5PbYt3p63vs3O5MTh2QvzbuON3uDOruoojtrNjqfmTuAW+uzqbgbAJwJs1u0MH+8e0/D+PdjMV9jyzut2XqD7vp/93tRoQCT/8+7efuP4jt0br91Azt2lHtvU7vDWLu4TfuCyoaVRuOwen/HhXtIcr4E/b1z5LtGKzQQAbfJnkGj3w2i/e/T/Vhzgdb30Kb3TKj65Gr/ZVQrxdXwGN/FGC93zUv/GVE/iVv/WWO/oxbn1vt71CL/iY2BqAb/o8M7ypB302T3l5H72Vu72MW+UJS/gYN8As+bqX1v2sRzq9R7QuV7ryAz4Jk6Sjc/0ZiDB32h1A3/iwdvjVp72/L32Bn/xLs/1Dx/3EX/53kfOoX33BS/tNf/yfB/45a73YA331y739M3tzTvrEO3e7wv6TS76sO/6lI3q6O71/m7KIuMSvU/ztA78tl75V//40h/5tm/6Ny/0Bq7Hn2Bwn5D5lbf5H6zfkJ/Wwt/mxD/ZjH78506Yg7/cZsBmjBEWFt/2GG/0pe/r//8NAoE4iscAoGhhkK0rGkWaCq89CjNa33auExC9l0lnPCKTyiUgOHQVdbwn6ce8YrNaXYEwG1i3Yu1vShWFd+cql7UOxIzmc7opfEdnc2raiT/NrLzByUgNBtTtPdX5reWNQWY1nj2qDdZFZmrqTCgspDgobI5KWb4lHqYJvsUZXhpNUlUCKA713TkCpqyuteqlygED4VLqkh7bDc7W9mAiP18lKAg0EEwXQmeWCf++Brr1YtNwp8Q+LZMn/7UN+o57d5/CEssaZ2eaD6HD3/crLUAQIJCCPxQD7DHZxs/UGlXgzrhjSGeeMoTMbtyqyI6VOIl8gi1Ul6sgPnrnLP+mI6nS4AAGBRdME+Api0J5rmzuekglIq2U+Xrsw4ni541KvCB27Bnyog+K61aKIWojaEOoVqFGECBBgoAIND0uAikUwNGdSZm+YGRSH8qFUonYK/uEJ1oXqEK+hYLwqpK8LahO5Cv4nsAdzo7UrHpTcc52Z32uBdp2rF8SRnXOfbwUssbBTCqPAPzRM2lShWlhIqB6tWoBrQ/Aji17dmzXrAkIoK17tu3VECzsDm4Bwm3cwYP3Xq2gwnHdF6rdzt2cdnJrzKfLfn77N3bZw4tL7w67unHx44svN39Ae/H27t/Dj387vXn2rMOLJy9/P//3n0rTVAYmBxFIoAAFIpj/oIIGLtjgggc6GCGDEkoIIYUOWnjhgxpiyGGDGXpYIIghHjQiiSaGiKKHKnLIooYuXggjhQ3sBSASWW3V1VebHEbGKD3uqAmQWAx5RZEJ/Zgkj0oKyaQ2TkZCQI02GgGTQDMRCSUkRy7BpRJeJgEmEmIipuUYZMphphholrKkm01uIiWVWRy0BZt6qGlnnj6++WSfkdxJw55B+gmnoYXiM+Wcf245aJaMnumokZIiCemalHaJ6ZeaJiHnotkEusMSCygqqqVfuLTpqQkc9J+qhybBagJhOrpAqrSeigKrt47pKAOlhkrLPwfN+mqin4J6xANeSDANQcamQIEMuFFT/2yvRoABwQOPwiLAA1lpBW0KEgTkmgSZHkGBQAJB4GqZTIAhLgoPKKCADGBM6YwEBBQAkwLb4ootgQ04MIC1aR5BwLa4tSvvAgQw0KxAAF/brQO8BqxDsw1I3IC8ACTgALsOHIxwleUO9DEsSZVTKrJjeGFEATmgPEFfCReQLW4O3Iztutp+puy6AkCgAAQ967DA0AKd2+kRXCmgWgPUID0DAwVgjbXIVafAwNAFH+i0EQmsG5MCJc8QsxxLh42E2lIU8EDZXBuUA24EBIRx2m6ve/ESb8+AMjXeim0EuOt6XLgOU0M3TdMJI/FA1lhDwDIKFLj7cj8z01KANIBfEf8BAUrPSgHo8ApAQbkQPJ5FAR5HcDZXYhQAgUsKN5C4Fq/PMPsWYLAtBhgTJDAzbi7rAAbWAiQwQdtkUGMNcZkbifXZMyM/g9IDREAQ2dmnTXDfaCckgdIyNGD5l/cS4HzrRLaeflRsq6/5SsaHrZoYcltTAAUK8Ox3YXtAucTQCXVBYABb20IntmIv32mhExM4iARiJ4YEZCVrC9QCvlQgEPDVbQAPA0AHtwCQBPJrSxAgDgmfl4WiqaYLAtDbZ7zAAJEJoH5IUEAEplaAZunwCABUYA7ktwUeSuAgEhSea7JWOfuRZmYTAwAAx4DDK1EPdboogCi2wIBpKGBqOvL/Yky8BcEsfHFpzxJgCuIlhiqiQGQg3AE2nEdDJiRAXfbaErsAYEcxWKlvMFPbw4JoBHW5Zl1ZXAIiiQYAI2qhkVe649+wkUIoDuZXB2HA1RbJhAVg7QHkY8LVeDXKUfWLAREg2RgWILpt/WoMDDAdASJAMQDJCpCueoDNIjEAhUGiQADgJSQSILl+QeIBtwTZGCZgswkQ4H2uI4DfWjKGb6mGApTEJDfHZjBN5FIT1hTnNrEwzm6iM53qhAapvhmJdp5yndlgQNEGEBAFlPMI9FSAPWWSz4R5C1zSvAJuvsU0mAX0oGIgl0CiCQmGmgsSDxMIJE1IrYpqYaLUMOQR/zSK0Sx4lKNjwyEEWHlBkpp0CyEbWTyTAJChrTGjgoupPP1xxcEFUAs3nVpOsyC3nxltf0Mr2tG28FN2BdWEbBvoqJY6hjKm7I1qfOpUpQpTql5VDIej6Bi2SjWtLk13WmCcahwnBrJaI1w1LQgBCBI1AJguKm71Qly3wLvYJeCMWLir7MTE17z61XZNeEDuaCdY3InVnGHzn8ha6rMTMJZ5AoQsBRo7WbJUVrIcXGxmHSsH9rlvTaBVKxlGy9QvxU+kNEjtWgvSw6xEYADV0GoDYCvb0y3hgEQjogEVgEDeMtC3u91gFhoIRL1ewbgPFJPSJliN7ynVuQSAbkYFIP9d6oLUurfFLhaau10XYmGIW/soE8RbRNWiwLyPRC8VI5DEASzxiO5VogJ62dp7cIUaMbFvFvLbgP2KIY1hFIhXyCgTMRZYCwJGcIDL+ADkktLBEGaCGAVAMvBeocIXnuMjx4dhCnuYwxrmLhYaeTTyMvJn6xWDiVe8BUn6k8VLw+d9/SEBz/2SvSi4MasuCchUrtKzVQJySjNKZCEn7ZUAiCUglcxklTqAXwkIpxZCJmUqZ8HKnsMyFrQ8ZXdWOcpbBvPuqOmSc5a5mv+UmZlJuGYdYLOtb4az6ORc4zvjOc963jOf+6wS7tWSeMEUXQQELcso82vOVkN0ARTdNUb/OxoFN4xhpJcM6WJ2oa0c1lWmKbBpkHX608XLpqhDHYllUXOZWkC1A1TtU9W0upihoOhplRCymHDMz6PIL+KQPK6w+lrSUMWSgoftySSksWzHRkKysdjgoRF7rEtzNYiHRu0lVHiKZ532GLJNOBl/bQww7mkWxt1Vti37CF4VQLp1vYQeJtFe1qVtvGfGXyx04gGy5WKCi/uvffOwt/pOX8CDO3B+Cxzg/e5uDhXogP8CsuEOeHgXq5uziUNcqReneMQ3nnH5wreW7H5jbKGZlXbrgIchP7loiwUQ9ubQ5U90d5S8sr0oR8XmB8K5XSEw5crJzbA/j1tghx70nhu9/+gJALqYwPAJ0Xltjk4HANQ/rISpV13qI8+6AJ8OMat/6Zk0g7nYATBzMpT97DTxHApe3vK2q53mDBwaKHGrBOcpsgsRX9cEmTu0vu9dIIBXKt/dWN3Ck6mMXgF7EhRPCw47nvE7XNfiIU/5x4P1Sk1g7+FE4eMsdH7zmaf76BUp90joUQbKFLdMVH9tJdDLwqzScexJNgDaT8P2uJf97a+Z+9m3MiCjKyUghW+rRhffNcd39EuHj3wTGp/4KmXYuXJ2QeqThcMJwL71oYzrWsdq1tQA/+nLb/7zoz/96t8fTa/ZfkDaHaTx7+78rzBCTdxfE6OLE8r70v9O/Z/bBP9gurxeiRXgFVDAAY4UMHXOSTFgDq0fKSEIzynYBNafNxWI81wQgmigSnGgmLBKBoLgB45BgkjeEZggh6Wg8CDICQqMiHBYOw0Me8ngQaDYsBTIDXaKIEHgFlCLhTVgBCqBFA3NBXIB2xjhF7BN0y0hEwWPAD3hZkUh9CwNhy2hFbINFlbhmmTh/CwNe/3guoAh/awJjYiMusCcGaZODwohEgxAvfhGErYRHKoGC3nR1KzG1AQYHkqNmDAAHxKAHt5hbwiiggFiIWpBVkDH8YDVIrqgDijiajziDERia3BYJTLi3BFHWbGX82xi/xgQ0SgHzBUC3pEiCphiGypBXZH/hRxGi9ro3UJZgeFpAQTRYn/NIpnYoi7m4hhg1ySmwC9q3/MAo64Q4zDqQjGiACR9XhYwo44941mpjciw12zFERuqohEwgKtsoyxx4wCCjC6wii+K46aNo66YYzmSYzB+GpiRGZ1YyzuaUzwGm0HQYwneIyDdiq200j5GGj+2naM9WfYFmDF0XzYiZEIq5EIyZEM65ENCZERK5ERSZEVa5EViZEZq5EZyZEd65EeCZEiK5EiSZEma5EmiZEqq5EqyZEu65EvCZEzK5EzSZE3a5E3iZE7q5E7yZE/65E8CZVAK5VASZVEa5VEiZVIq5VIyZVM65VNCZVRK5VRSZVVa/+VVYmVWauVWcmVXeuVXgmVYiuVYkiWASI4C+sPtVdqSHaTmdNIwqY9almVOeuI13tsmzEwDvB9J1NWygGPd6JhVzIxLsKIR+OVc5uTUTIDXJE7z/FDbYc1ihiMDJEDmgJJk/uGBHIwxPaaunOWscKYokUrbncCvNI+gceZjZmZLmOaOxU2xiBAoAQwoFYBkKo8OOOa5sMp/EEtL3FiqcObjMMAExA1lWtOuIOd/fGbgFNho7sqNlSax7MpkktAntIQ1/cpaIiZEgkHUhA1MQMDUEEQg4sbZgAEezoDcNEDRgNK6iON/7cySwaG9fFHU2AtuDEUOzAxxUM0b4k0OEf/h8pyAyFhDA8yKTIhhE1SDTLAKNoKneFIduzmPvsmENeBTAsAnEL4hcdjLbSrPeboGhnqn7nBF0+Bnd7qnFJXIvUAg0UyD0vCMyPzldkYkDj2LyCRR0SzZ7R0PGMSWu6zQkgEhfqYn4YjMDYUNq8hROBIpfmIPAMhoZUqOazTBD2CP1/CM3GxLtSiNDfEohGAjjtqTKGBoQPDMbcrNBGgplM7QzBQMJ3low3WFCMlNzrAc1RVVlbYQzziPDGBPnMrAbp2AjoYRjZYk2WjW3ayGiEYZmJ5FzFApke7CYh2IpOppOfyAk1LqAKin8Vzqn0LgbVIpLUzXfzXqiqZNcsz/i0CcWagC6KZu37pQKIvmTA/m5Wp8Atms0Ym6qp86agsFqto4T1agpaFe5GnA1bwZExgQhBzd5uKYZ+pc6q9NC/Ooy7Zw6rWS0LJYF0ORhWZOTawmgNd4AW5MGfaQjRfMzLmMqmswK5uiarQo67aUqYZCII5yRbXm1bnwz3kOABo+K1ewkgS4xB/lJ7AiLKjSCBqSatesSz0aq0Qia6xeCYZeya8mDa7NiqVe4xRRrHV97ATkl9Hop7UN08Wqq0AI6MkKRAC1a6lebLzqyg+Kwsk5T98JEptOEd7JxCeIkQ89a7Kanh0eLKB+6wn8bIu+TVaQW8R+ZJ1YDdTupmlOlycKuspoaiOZ/Qo3ipCkncBorus5kcpukua4ulPVVqdB5KoIUS2aee0JkC0JrWjXdg2YaRKqICeaheCsgMEtOedxWtOSutl00i0KZMWnOa1UPikUBW0/QJNifRUpOVLilmVrQhHa2kgIZpnbUm7neu7ngm7oiu7okm7pmu7pom7qqu7qsm7ruu7rwm7syu7s0m7t2m5YhgAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://www.cdc.gov/ncidod/dhqp/bp_hcp_w_hiv.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31902=[""].join("\n");
var outline_f31_9_31902=null;
var title_f31_9_31903="Skin sparing mastectomy flap development";
var content_f31_9_31903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Skin sparing mastectomy flap development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Development of the skin aps with a skin-sparing incision is similar to that of the larger incision, just in a smaller eld. Tension is placed on the breast tissue by pulling down on the breast tissue toward the chest wall or by pulling the breast tissue away from the skin. The skin is initially retracted away from the chest wall, with skin rakes or hooks as the plane is developed. As the dissection progresses, one can switch to hand retraction, occasional rolling the ap forward or backward for access. One could also utilize a lighted retractor in the context of space restraint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_9_31903=[""].join("\n");
var outline_f31_9_31903=null;
